Entities

Polaris executive assistant since2001, supporting Jon Flint and subsequently the healthcare team including Alan Crane. Previously supported executive leadership at Allaire Corporation.

Office coordinator at Polaris’ Boston office since2022. Previously an assistant office manager at Above the Rim sports complex.

Polaris portfolio analyst since2002, supporting finance and investor relations. Previously worked in audit, cost accounting and investment pension finance at John Hancock; studied finance at Siena College.

Boston senior operations associate at Polaris since2019. Previously worked at The Fulham Group, supporting office management and finance operations.

Polaris director of operations and limited-partner relations since2011, responsible for administration and special projects. Previously supported executives at Pixar and Sony’s Crackle.

Polaris founding partner with early-stage investing experience in medical and information technologies. Earlier venture positions include Burr, Egan, Deleage & Co.; co-founded Polaris in1996.

Polaris director of legal and investment analytics in San Francisco since2019. Previously a quantitative-analysis manager and senior corporate paralegal at Latham & Watkins. Studied mathematics at UCLA, obtained paralegal certification at San Francisco State and an MBA at Berkeley Haas. Distinct from Form Energy’s attorney and interim general counsel Brian Lewis.

Singapore partner at Polaris focused on healthcare technology, medical technology and care delivery. Earlier roles span Singapore’s SingHealth, National University Health System and Ministry of Health.

San Francisco accounting manager at Polaris since2018, working on management-company accounting. Previously spent more than fourteen years in accounting positions at VantagePoint Capital Partners.

New York principal at Polaris, focused on biotechnology and healthcare; joined in2022. Previously worked in Bain’s healthcare practice and helped establish Glympse Bio’s diagnostic technology.

Executive assistant supporting Polaris’ New York office since2023. Her earlier executive-support career spans finance, hospitality and other industries, including Goldman Sachs and SBE.

San Francisco chief financial officer at Polaris since2017. Oversees fund accounting, reporting and compliance and works with the finance, investment and legal teams.

Boston-based founding partner who established Polaris in1996 with Steve Arnold and Terry McGuire. Earlier venture experience includes Burr, Egan, Deleage & Co.; his career began in law.

Boston executive assistant and office manager at Polaris since2018. Previously provided administrative support to nonprofit organizations and worked in historic-site interpretation.

Polaris general counsel and chief compliance officer in San Francisco since2019. Supports legal, regulatory and operational work, fund formation, management and portfolio financing transactions.

Polaris entrepreneur partner since2002, building and financing healthcare companies. His company-building experience includes Zag Bio and multiple founder, chief-executive and chair positions.

Singapore entrepreneur partner at Polaris since2023, working on building and scaling healthcare businesses. Previously a life-sciences investment director at Temasek International.

Geney Park was published as a Bioluminescence Ventures Operating Partner who joined in2024. Previously she supported Ossium Health’s executive leadership and managed events and marketing for its bone-marrow banking business. Earlier work covered marketing and communications in health, wellness, fitness and technology training. She studied psychology at UC Riverside. This describes the archived2024–25 manager roster; continuing2026 BLV employment is not independently established.

Fund controller at Polaris since2022, responsible for fund administration and reporting. Previously an audit senior manager in BDO’s asset-management practice, with venture and private-equity experience.

Shailaja Uttamsingh joined Bioluminescence Ventures as Partner in2023 and led clinical and translational-science work. Her earlier oncology-development experience includes Exelixis, Celgene/BMS, Oncomed, Genentech and Amgen. She trained in biomedical sciences at Mount Sinai, biotechnology at Maharaja Sayajirao University of Baroda and physiology at Presidency College. Her university’s March2026 biography describes the BLV role as past and identifies subsequent clinical/venture advisory work; she is not presented as a current active BLV partner.

Andy Seid was published as a Bioluminescence Ventures Partner who joined in2023. Earlier he advised life-sciences companies in Bank of America’s global healthcare investment-banking group and held related positions at Leerink and UBS. His operating experience includes business development and strategic finance at Genentech and Sangamo. He studied molecular/cell biology and economics at Berkeley. The archived2024–25 BLV title does not establish a current2026 appointment or ownership of former-employer transactions.

Chloe Kim was published as a Bioluminescence Ventures Partner who joined in2022. Trained in biomedical engineering and cell biology, her expertise spans regenerative medicine, oncology, immunology and neuroscience. Earlier she worked in biopharmaceutical business development and strategy and consulted on life sciences at Charles River Associates. She earned Wisconsin–Madison biomedical-engineering graduate degrees and a Berkeley undergraduate degree. This describes the archived manager roster; her current public self-profile lists a stealth startup, so continuing BLV employment is not inferred.

Kouki Harasaki founded Bioluminescence Ventures and was published as its Founding/Managing Partner. Previously he led life-sciences investing at M12/Microsoft Ventures and was a senior partner with Andreessen Horowitz’s Bio Fund. His earlier work included drug discovery, pharmacology, finance and business development at Novartis and Baxalta/Shire. He studied molecular and cellular biology at Cornell, earned a Cambridge clinical-biochemistry doctorate and a Harvard MBA. The BLV role is documented by dated primary announcements and the archived2024–25 roster; continuing2026 manager activity is unverified.

Atlas AI develops geospatial AI software and data products that help organizations understand local socioeconomic conditions, detect changes and forecast demand across global markets. Its platform turns satellite imagery and other location data into analysis-ready geospatial features, production-scale models and developer tools for data scientists. The Aperture product family supports access to hyperlocal indicators and faster monitoring of changes, while applications include infrastructure planning, site selection, market segmentation, logistics, manufacturing forecasts and monitoring vulnerable communities. The company combines economics, earth science and machine learning to provide insights in regions where conventional data are sparse. Founded in 2018 as a public benefit corporation by Stanford researchers Marshall Burke, Stefano Ermon and David Lobell, it is backed by The Rockefeller Foundation, Airbus Ventures and Micron.

ScaleFlux is a semiconductor company developing storage and memory controllers, firmware, software and enterprise solid-state drives for AI, cloud, data-center and edge infrastructure. Its computational-storage technology embeds functions such as transparent compression into flash drives to reduce data movement, host-CPU work and storage bottlenecks. Current products also target the memory needs of AI inference: workload-aware SSD capabilities and flexible data placement help manage write-intensive key-value caches across GPU memory, host memory and SSD tiers. The company develops PCIe SSD controllers and Compute Express Link memory controllers, supplying components and complete solutions to storage vendors, system manufacturers and cloud providers. Founded in 2014 and headquartered in Milpitas, California, ScaleFlux is a published Micron Ventures portfolio investment.

Leads Atlas AI and serves on its board. Background in renewable energy, semiconductors and development data; previously at Incandescent, Premise Data and Astonfield Renewables.

Works on geospatial products with Atlas AI’s Innovation Team. Background in drone geotracking, remote sensing and autonomous systems research.

Atlas AI co-founder and board member. Stanford professor researching applications of data science to agriculture and food security.

Develops, tests and delivers geospatial analytical solutions for Atlas AI customers and partners.

Leads Atlas AI’s Innovation Team. Research and industry experience across computer vision, machine learning and global satellite-image analytics, including the European Commission Joint Research Centre and DigitalGlobe/Maxar.

Solutions engineer working with customers across Africa. Background in geospatial, remote sensing, drone and healthcare startups, including leading systems work at Flare.

Published in Atlas AI’s current board directory with Textio as her external affiliation.

Atlas AI co-founder with academic expertise in earth-system science, agricultural economics, food security and environmental research.

Atlas AI board member whose published biography identifies him as an Airbus Ventures partner overseeing EMEA activities and strategic links to Airbus.

Works with Atlas AI’s Applied Data Science team to turn research into products. Background in statistics, sustainability and sensor-based data research.

Develops machine learning workflows to track socioeconomic indicators. Previously worked on plant-image analysis and species identification at Greenstand.

Atlas AI co-founder who advises its team on machine learning technology. Academic background in computer science and AI research at Stanford.

Shapes Atlas AI’s development analytics services. Previously led infrastructure analytics at CPCS; background in systems planning and investment advisory across energy, transport, water and urban infrastructure.

Atlas AI board member and independent adviser. Previously held senior strategy, program and innovation roles at The Rockefeller Foundation.

Investor Relations professional at Mammoth Scientific. Her published responsibilities include coordinating projects and investor and adviser relationships, drawing on project management, business development and customer-facing experience. Her own biography lists prior business-to-business marketing and project-management work and a degree from Taylor University.

Global Investor Relations professional as listed in Mammoth Scientific’s public directory. The firm describes international operating experience, business relationships across different regions and support for its global investors. The linked individual biography returns a missing-page response, so more specific prior employers, education and appointment dates are unverified.

General Partner and Chief Legal Officer as separately published by Mammoth Scientific. Her legal work covers company transactions, governance and regulatory and commercial risks for founders and portfolio companies. She has served as in-house general counsel and outside counsel, and her own biography lists Northwestern College and Mitchell Hamline School of Law.

Vice President of Finance and Business Development as listed by Mammoth Scientific. The public directory describes responsibility for investor relations, portfolio due diligence and business development supporting the executive and investment teams. The linked individual page currently has no substantive biography, so further career and education details are unverified.

Co-founder and General Partner of Mammoth Scientific. He works on private-investment technology infrastructure, automated workflows and communications with investors and portfolio companies. His published career includes Orion, co-founding Mineral Interactive and a marketing role after its acquisition by Carson Group; Mammoth’s biography also identifies him as CEO of Milemarker.

Co-founder and General Partner of Mammoth Scientific, also published professionally as Kim Mackrill. She works on organizational integration, operations and data and technology processes for the investment platform and portfolio companies. She co-founded Mineral Interactive, which was acquired by Carson Group in 2018, and her Mammoth biography describes subsequent marketing and client-experience work and a role at Milemarker.

Mammoth Scientific is a venture capital firm focused on health science and technology, including medical devices, biotechnology, healthcare software, financial technology and data-driven healthcare. Launched publicly in 2021, it combines physician entrepreneurs with investment, operating, legal and investor-relations specialists to support companies beyond seed stage through regulatory approval, reimbursement and commercialization. Published investments include MiRus medical devices and MRIguidance’s BoneMRI imaging technology. Mammoth Scientific, LLC is the private-fund adviser; Mammoth Investors, LLC is its parent management company, as disclosed in Vestia’s 2025 adviser brochure. Mammoth’s June 2024 legal disclosure describes an Indiana registration exemption. Its January 2024 SEC filing is an exempt-reporting-adviser final report, not evidence that the whole business closed. The website lists nine team members, with individual biographies sometimes providing more specific operating titles. The first health-and-technology fund advertises a $100 million target; this is not a verified final raise. Legal series are recorded separately where supported, with reported sold capital qualified to its filing date.

Neurosurgeon, co-founder and General Partner of Mammoth Scientific. He focuses on medical devices, healthcare software analytics and surgical technologies, helping companies develop clinical evidence, regulatory pathways and value-based reimbursement. His published background includes Duke undergraduate and medical education, Johns Hopkins residency and fellowship, and neurosurgical practice in Charlotte.

Co-founder and General Partner of Mammoth Scientific. His published work covers portfolio-founder support, investor relationships and financial, tax and operating strategy. He previously led a physician-focused wealth-management firm and has invested in private healthcare, fintech and other businesses. Mammoth’s fund committee and legal fund filings also identify him as CEO and operating manager; his own biography lists Indiana University and Harvard Business School executive education.

Bioluminescence Ventures (BLV) is a San Francisco biotechnology venture manager founded by Kouki Harasaki. Its documented strategy supported breakthrough biology, drug-discovery platforms, genetic medicines and computational biology, including neuroscience drug development. Its historical portfolio includes Cerevance, Ensoma, Nido Biosciences, ReCode Therapeutics, SURGE Therapeutics and GEMMABio. The firm emerged from stealth in November2023 reporting USD477M assets under management across two separately registered Delaware funds; that AUM is not an additional cash raise. Primary SEC filings independently document USD350M and USD127,123,383 fund interests sold. This profile preserves the firm’s historical investment activity and dated team roster. Asof October7,2026, its original domain redirects to a parked-domain sale page, and current professional biographies identify several published partners as former BLV staff. Continuing operations, a current team and new-investment activity cannot be confirmed from a live manager website. The archived logo, biographies and portfolio are identified as historical publisher material, rather than a current operating-directory claim.

NovaCapital is an Italian investment holding company owned by Merloni Holding. It backs entrepreneurs and technology businesses in Europe and the United States from seed-stage development through IPO, with a long-term investment horizon. Its focus includes biotechnology, healthcare, financial technology, deep technology, space, sustainability and smart urban development. The group also provides growth capital and industrial expertise to established companies through private-equity activities and invests in renewable energy.

Business administration graduate with five years at PwC Milan; joined NovaCapital in 2022 after a role in the luxury sector.

Joined NovaCapital in 2021 following audit and M&A transaction services roles at EY and PwC; studied business at Bocconi and Grenoble.

Joined NovaCapital in 2023 after bachelor’s and master’s degrees in finance at Bocconi.

Corporate finance graduate from Luiss with experience at PwC, Kartesia and Alantra, and co-founder of a B2B SaaS startup.

Also Managing Director of Pragma Invest. Has investment banking and private equity experience at Salomon Smith Barney, Flemings and Synergo; joined Merloni Holding Group in 2013.

Executive Chairman of Ariston Group and Merloni Holding, with earlier McKinsey experience and a Bocconi business degree.

Joined NovaCapital as Management Assistant in 2022 and became Office Manager in 2023; previously Executive Assistant at Ariston Group and Modiano&Partners.

Ariston Group finance and treasury executive; coordinates Merloni Holding Group’s financial matters since 2008.

Shelley Graves joined S3 Ventures in 2009 and manages accounting, financial reporting, budgeting and compliance as Controller. She also supports HR and administrative operations. Her prior accounting work includes Union Pacific Resources and Cable Com.

Kathryn Deebel joined S3 Ventures in 2025 and leads marketing, community building, the firm’s professional network and internal operations. Her prior experience includes Quiet Capital, Gaingels and Golden Ratio. She studied finance at Penn State.

Will Omberg, also named William Omberg in the firm’s fund announcement, joined S3 Ventures in 2025 and is currently Senior Associate. He previously spent four years in technology investment banking at Jefferies working on M&A and equity financings. He studied commerce at the University of Virginia.

Anthony Marfisi joined S3 Ventures in 2024 as an Associate evaluating investments and supporting portfolio companies. He previously worked at DCA Asset Management on technology-company analysis and transaction advisory, and studied finance at Nebraska.

Kevin Haley joined S3 Ventures in 2025 as an Associate. He previously worked as an early product manager at Starburst Data on enterprise and SaaS products. He holds business and finance degrees from Boston College.

Aaron Perman is a General Partner at S3 Ventures investing in early-stage business technology and healthcare technology. His portfolio work includes Mythic, Hydrolix, Crogl and Sunthetics. He previously led Qualia Media through its acquisition, invested at Western Standard and worked in corporate strategy at Southern California Edison. He studied international business at USC.

Joe Curry is a Principal at S3 Ventures, evaluating investments and supporting portfolio companies. His current firm biography and team directory identify this role; a native employer-published portrait accompanies the biography.

Nicole Bentz joined S3 Ventures in 2021 and is Vice President, evaluating investments and supporting companies including BrainCheck, QbDVision and Sunthetics. Her previous work includes Flyover Capital and PwC. She studied accounting at the University of Kansas and previously held a Missouri CPA license.

Eric Engineer joined S3 Ventures in 2018 and is a General Partner. His portfolio board work includes Buzz Solutions, Kamiwaza, MontyCloud and QbDVision. He previously led Invodo through its acquisition, invested at Sevin Rosen Funds and worked at Microsoft and Trilogy. He holds an MBA from Harvard and computer-science degrees from Rice. Eric Engineer’s current S3 Ventures biography explicitly lists Kamiwaza among his portfolio boards; the January2025 Kamiwaza SEC filing independently names him as a director. This institutional affiliation is distinct from a personal investment.

LifeRock Ventures is a life-sciences investment firm backing therapeutic innovation, including gene and cell therapies and precision medicines. Its public website also describes investments in diagnostics, medical devices, digital health, healthcare services and applications of life-sciences technology beyond healthcare. Its verified neuroscience investment is Cerevance, a company developing precision therapies for central nervous system diseases using the NETSseq human brain transcriptomics discovery platform. Cerevance explicitly named LifeRock as a new participant in its USD 47 million Series B-1 extension announced on 25 April 2024; the round total is not LifeRock’s individual investment. The website identifies the brand as LifeRock Ventures, Inc. in its copyright footer. No verified named management roster, legal fund vehicles, fund-close sizes or individual investment amounts are published in the primary sources reviewed. The separate LLC trademark applicant has not been established as the same contracting entity, and no speculative family-office, founding-year or headquarters claims are asserted.

Nadia Tarolli Schmidt is a Swiss lawyer and certified tax expert and a partner at VISCHER since 2010. Her current VZ corporate-governance biography explicitly lists her board membership at BiomedVC. She studied law at the University of Basel and advises on tax, social security and corporate matters. Her external board and law-firm affiliations provide identity context and are not treated as personal investment checks.

Ulrich Vischer is a Swiss attorney and senior counsel at VISCHER. He previously headed legal and tax work at an international insurer and served twelve years in the Basel City government overseeing finance. An official November 2018 Swiss commercial-register notice appointed him chair of BioMedPartners; the latest current primary firm team directory does not list statutory directors, so the legal-chair title is explicitly qualified by its last directly verified appointment notice.

Ulf Grawunder was appointed an entrepreneur in residence at BiomedVC in April 2026. He co-founded and leads T-CURX and previously built 4-Antibody and NBE-Therapeutics. He trained in biochemistry and immunology and earned his doctorate at the University of Basel. These are institutional manager affiliations; no personal portfolio investment is inferred.

Olivier Morand is a venture partner at BiomedVC and senior adviser to Scenic Biotech. His earlier work includes co-founding and leading Azafaros and pharmaceutical development roles at Actelion, Idorsia, Merck and Roche. He studied biology and genetics at Paris VII and executive management at IMD. These are institutional manager affiliations; no personal portfolio investment is inferred.

Mattias Ivarsson is an entrepreneur in residence at BiomedVC and founding CEO of Salvina Therapeutics. He previously founded Inositec during an ETH Zurich fellowship; that company was acquired by Vifor Pharma. He trained in biomedical engineering and pharmaceutical sciences and earned a doctorate at ETH Zurich. These are institutional manager affiliations; no personal portfolio investment is inferred.

David Urech is an antibody engineer and biotech entrepreneur appointed as a BiomedVC venture partner in April 2026. He co-founded Numab Therapeutics and Yellow Jersey Therapeutics and previously led research and development at ESBATech. He studied biochemistry at the University of Basel and molecular biology/neuroscience at the University of Zurich. These are institutional manager affiliations; no personal portfolio investment is inferred.

Claudia Ulbrich is a physician and biotechnology entrepreneur appointed as a BiomedVC venture partner in its April 2026 announcement. She co-founded and led Cardior Pharmaceuticals through its acquisition by Novo Nordisk. Her background also includes LipoNova and advisory work in biotechnology strategy and corporate development. These are institutional manager affiliations; no personal portfolio investment is inferred.

Marianna Feretzaki joined Biomed in 2026 as a senior associate. She previously led scientific work and acted as CEO at Rejuveron Telomere Therapeutics. She earned a genetics and genomics doctorate at Duke University after undergraduate biology study at the University of Crete. These are institutional manager affiliations; no personal portfolio investment is inferred.

Morgan Hunter joined Biomed in 2022 and is listed as investment manager with BiomedVC. His earlier entrepreneurial research included the planned ETH Zurich spin-off Emuna Therapeutics. His scientific training covers pharmaceutical immunology, vascular biology and protein engineering. These are institutional manager affiliations; no personal portfolio investment is inferred.

Stefan Fäs joined Biomed as group CFO in 2010 and is currently listed as CFO and partner for both manager teams. His previous work included Helbling Corporate Finance, Ernst & Young and UBS Asset Management. He holds graduate degrees in biology and economics and a certified-auditor qualification. These are institutional manager affiliations; no personal portfolio investment is inferred.

Valentin Piëch is currently listed as managing partner with both BioMedPartners and BiomedVC. He initially joined Biomed in 2015 and founded VP Venture Partners in 2020. His earlier experience includes Nextech Invest. He holds a neuroscience doctorate from Rockefeller University and graduate degrees in cognitive/neural systems and mechanical engineering. These are institutional manager affiliations; no personal portfolio investment is inferred.

Markus Hosang joined BioMedPartners in 2004 following venture investing at MPM Capital and approximately two decades of pharmaceutical research leadership at Roche. He studied biochemistry at ETH Zurich and undertook postgraduate training at Stanford and the University of Washington. These are institutional manager affiliations; no personal portfolio investment is inferred.

Aristotelis Nastos joined Biomed as managing partner in 2023. He previously headed life-sciences investing at NRW.BANK and worked at Peppermint and Creathor Ventures. His scientific background includes biology, a doctorate in cell biology and postdoctoral research at King’s College London. These are institutional manager affiliations; no personal portfolio investment is inferred.

BiomedVC AG is a Swiss life-sciences venture manager established in 2021 to continue the investment legacy of the separate BioMedPartners AG. It supports scientific founders building venture-backed biotechnology companies, typically entering at seed or SeriesA and reserving capital for subsequent rounds. Its geographic emphasis is continental Europe, particularly Switzerland and Germany. The own current public directory identifies six core investment/finance staff and five venture partners or entrepreneurs in residence; Michael Wacker, Valentin Piëch and Stefan Fäs have explicitly dual manager affiliations. The successor is a distinct Swiss legal corporation, CHE-465.445.585, with its own 2023 statutory board notice, and not a renamed 2020 Noema buyer. The European Investment Fund identifies its actual legal fund as BiomedInvest IV SCSp, RAIF. Own site confirms an initial close but does not disclose its closed size or exact day; April16,2026 own release says it is advancing toward a second close. The widely reported CHF150M is a target, not a verified final fund close. New FundIV investments on the own portfolio include T-CURX, iDEL Therapeutics, Scenic Biotech, Dimericon and Dolthera, with research in advanced therapeutic platforms and genetic mechanisms. The inherited combined website also lists many BioMedInvestI–III companies; these are not automatically assigned to the successor’s investment ledger. The primary scientific investment focus is biotechnology and therapeutic development; AI or neuroscience eligibility is limited to actual relevant portfolio research rather than a generic label for every pharmaceutical company. Its authentic current own corporate wordmark and all published named operating-team portraits were retrieved from exact primary WordPress asset URLs. Board member Nadia Tarolli Schmidt is separately confirmed by her current outside listed-company biography; Ulrich Vischer’s legal-chair record belongs the earlier manager, with historical-source scope.

BioMedPartners AG is a Basel-based Swiss life-sciences venture investment manager founded in 2002 according to its current own website and the Swiss Biotech Association directory. Historical fund releases and partner biographies sometimes date investment operations to 2003; that operational-history difference is explicitly retained. The exact legal manager is identified as CHE-109.704.295 in official Swiss commercial-register publications. It invests in biotechnology, pharmaceuticals, diagnostics and medical technology in Switzerland and neighboring European countries, often leading or co-leading early-to-mid-stage rounds. Its neuroscience relevance includes Noema Pharma’s investigational treatments for central-nervous-system disorders and Aleva Neurotherapeutics’ deep-brain-stimulation technology. Its BioMedInvest I–III portfolio is currently described as in the harvesting phase. The public team filter specifically identifies Markus Hosang, Michael Wacker, Thomas Möller, Valentin Piëch and Stefan Fäs with BioMedPartners; overlapping staff are distinguished from the separate successor BiomedVC AG, established in 2021 to manage newer early-stage investments and Fund IV. Historical 2020 Noema funding remains attributed to BioMedPartners rather than migrating to the later corporation. BioMedInvest I is primary-confirmed at CHF100M with a 2003 closing year; Fund II is CHF106M with a 2009 closing year; Fund III finally closed at CHF100M on March1,2018. Where only a year is published, exact close dates stay unknown. BioMedCredit is a historically documented separate mezzanine vehicle; a 2009 original profile reported CHF50M and a 2006 close, but no independently retrievable own final-close notice has been verified, so its numeric fund-close fields remain unknown. Aggregate committed capital and AUM are not added as another fund. The authentic historical green-diamond brand mark is retrieved from an explicitly labeled external logo mirror linked to the firm’s own LinkedIn identity; the original firm-hosted historical asset is unavailable. This is distinct from current BiomedVC’s own wordmark and unrelated US BioMed Ventures.

Evercurious VC is an Athens-based venture capital manager investing in European deeptech companies founded around scientific and engineering expertise. It backs pre-seed, seed and Series A companies developing defensible hardware and software technologies in robotics, manufacturing, medical devices, health technology, life sciences, energy, climate technology, advanced materials, mobility and agriculture. The firm connects Greek technical founders and research with other European innovation hubs and supports the commercialisation and international scaling of research. Evercurious VC AEDAKES manages Evercurious Fund I with backing from the Hellenic Development Bank of Investments.

Radix Ventures is a venture capital firm backing research-intensive startups across Central and Eastern Europe and selectively elsewhere in Europe. It invests in technologies moving toward commercial deployment in renewable energy and storage, industrial automation, robotics, AI, autonomous transport, space, advanced computing and defence or dual-use applications. The team supports intellectual property strategy, pilot implementations, business models, revenue development and subsequent financing. The firm operates through Radix Ventures GP SARL in Luxembourg and Radix Advisors Sp. z o.o. in Warsaw. Its current manager portfolio is published separately from the partners’ earlier investments and exits.

UiPath Vice President who helped scale the Bucharest startup into an international robotic process automation company.

Also known as DJ Nag. Intellectual property strategy specialist, President of Innovaito LLC and Professor of Practice at Rutgers University, named to IAM Strategy300 in2026.

Operations and business development professional with experience leading strategic initiatives and operational processes; studied economics and digital transformation at Koźmiński University.

Hungarian technology investor with experience in strategic exits including Tresorit and Index Tools, and formerly Head of Yahoo! Labs.

Microelectronics PhD with postdoctoral research experience at INSA Toulouse. Previously Managing Partner at Polish deeptech investor PIBIR.

Experienced fund finance executive who served as CFO at Nomad VC and Valuetech. Brings financial due diligence and transaction experience, with exits including Booksy.

Finance and accounting professional with experience in deal screening and portfolio metrics; holds a master’s degree in accounting and finance from the Warsaw School of Economics.

Technology entrepreneur and investor; formerly founded and chaired MIT Enterprise Forum Poland and served as Managing Partner at Valuetech, supporting Polish deeptech acceleration and seed investment.

Technology product professional with experience at Google, Microsoft, AWS and Snowflake; an angel investor active in Ukraine’s startup ecosystem.

Medical-device executive with more than20 years of industry experience. Worked at Medtronic’s EMEA headquarters and helped grow TriVascular and LimFlow through fundraising and acquisitions. Supports early-stage Greek medtech companies as an adviser and angel investor.

Corporate finance and investment professional with more than20 years in M&A and investing. Previously an investment director at Newberg and Valuetech, with IPO and exit experience including ML System, Sat Revolution and T-Bull.

Ken Chin is a partner at MQB Partners, a medical doctor and healthcare business owner with more than20years of experience. He previously co-owned a general medical practice acquired in2022 and is a Fellow of the Royal New Zealand College of General Practitioners. Since2016 he has provided clinical assessments of early-stage healthcare investments and strategic advice to healthcare businesses. His earlier research covered endocrinology and urology. He holds medical and human biology degrees from the University of Auckland and a postgraduate travel-medicine certificate from the University of Otago.

Scott McPhee is a partner at MQB Partners and an entrepreneurial scientist developing novel medicines since the late1990s. He participated in early gene-therapy programmes for neurodegenerative conditions and initial central nervous system AAV trials. He was a founding executive at Asklepios BioPharmaceutical, acquired by Bayer in2020; co-founded Chatham Therapeutics, acquired by Baxter; and joined the founding team of Bamboo Therapeutics, acquired by Pfizer. He also co-founded Torque Bio. He holds a molecular medicine doctorate from the University of Auckland and a public health master’s degree from Harvard University. Historical company transactions are not MQB investments or fundraising without separate proof.

Marko Bogoievski is a partner at MQB Partners. He previously led Infratil and infrastructure investment manager H.R.L. Morrison & Co as CEO, during a period in which their funds under management grew from $2.1billion to $25billion; those historical assets are not MQB fund closes. His career includes finance, sales and investment management across New Zealand, Australia and the United States. He holds a commerce and administration degree from Victoria University, an MBA from Harvard Business School, and is a Fellow Chartered Accountant.

MQB Partners is a Wellington, New Zealand healthcare investment partnership operated by MQB Partners Limited. It invests in a concentrated portfolio of healthcare companies approaching clinical, regulatory or commercial inflection points. The partnership targets medical devices, robotics, artificial intelligence, novel therapeutics and clinically significant digital health. Its partners commit substantial personal capital before inviting aligned investors, including family offices and specialist co-investors, to participate. Its active ownership model combines clinical and commercial judgement with governance, financing strategy, R&D, execution and exit preparation. The current four-partner team comprises Marko Bogoievski, managing partner Caroline Quay, scientist Scott McPhee and physician Ken Chin. Its official portfolio identifies neuroscience drug developer Cerevance and robotic airway-management company Spiro Robotics. Cerevance issuer announcements independently confirm MQB participation in the April2024 SeriesB-1 extension and May2026 SeriesC. The website’s legal terms identify MQB Partners Limited as the operator; the brand is not presumed to be the direct legal subscriber for every managed investment vehicle. No publicly verified LP fund cash close or fund size is asserted. Prior Morrison & Co/Infratil assets under management and historical company exits belong to the partners’ earlier careers and are not MQB capital raised.

Dave Maldonado was announced by Ramen VR’s CEO in February 2023 as the incoming design leader alongside art leader Giancarlo Surla. The issuer describes previous World of Warcraft and New World design leadership. A continuing 2026 staff role, exact employment start day and current photograph are not independently disclosed in the accessible primary sources.

Chandani Battle is the named author of Ramen VR’s December 2024 hackathon article. This primary publication establishes a credited contributor affiliation but does not disclose a precise employment title, start date or continuing staff status. No executive, marketing or operations position is invented.

Chris Gong co-founded the Unreal Engine AI assistant Flopperam with Ryan Thomas. Ramen VR’s June 2026 issuer announcement and Gong’s own acquisition post identify his joining Aura as Senior AI Engineer. His own GitHub account chris-gong links the Flopperam Unreal-engine MCP project now owned by Aura. This is a distinct person from the existing Arize AI engineer Chris Gong whose public profile is chrisgong52; their identities and affiliations are preserved separately.

Robert Espinoza’s own professional profile identifies Ramen VR and his 2026 Aura game-development work. His own earlier Paper Crane Games biography identifies an environment artist and co-founder, and provides the named genuine photograph. An unpublished current seniority level is not inferred. He is not automatically conflated with the historical Zenith credit Rob B.

Kristani Alcantara is identified as Director of Operations in Ramen VR’s December 2024 hackathon article and retains the Ramen affiliation on her own public professional profile. The historical Zenith press kit credits her as Operations Director. Meals for Unity’s own origin story also names her as a co-founder, a distinct outward nonprofit activity rather than Ramen financing.

Hisham Bedri is named in Ramen VR’s current public company directory and authored its March 2025 Speedrunning Game Development article. His primary MIT Media Lab profile identifies him as a former research assistant interested in spatial technologies, 3D displays and imaging. That historical academic affiliation and authentic MIT photograph are personal credentials, not an assertion that Aura is a brain-interface or clinical neuroscience product.

Giancarlo Surla is named in Ramen VR’s current public affiliation directory. The issuer’s February 2023 CEO letter announced his appointment to lead art direction alongside design lead Dave Maldonado. Surla’s own published professional recommendation identifies his role as Head of Art. He previously co-founded Paper Crane Games, whose own named profile supplies his genuine photograph.

Kevin Calderone is named in Ramen VR’s current public company directory and lists the company on his own professional profile. His own earlier game-studio biography documents programming and design work. An exact current engineering grade and appointment day are not disclosed in the accessible primary directory and are not inferred from third-party organizational charts.

Lauren Frazier-Silva, previously publicly known as Lauren Frazier, co-founded Ramen VR with Andy Tsen in 2019 and served as CTO. Her own current Silvermoon website identifies her as its founder after prior work at Google, Unity and Ramen VR; her older personal site still describes the Ramen CTO role. This Ramen affiliation is therefore historical rather than an assumed current executive appointment. Her own statement that she raised over USD46M at Ramen is a cumulative lower bound, not an additional cash round.

Andy Tsen co-founded Ramen VR in 2019 with Lauren Frazier. Its current primary company and Y Combinator profiles identify him as CEO, and the September 2026 Aura issuer release quotes him as CEO. Ramen VR develops AI agents for game creation and originally developed Zenith: The Last City. Company speed and market-coverage claims are not independently verified benchmarks.

Ammara Chaudhry is published by Blackbird Health as a certified registered nurse practitioner providing psychiatric care for children and families. Her biography describes nursing and specialized mental-health experience and study at UC Berkeley, George Mason, Drexel and Wilkes. The public clinical-network affiliation is distinguished from direct employment by the administrative management company.

Amy Edgar founded the original clinic behind Blackbird Health in 2014. Its current directory identifies her as a founder and publishes her nursing education at DeSales University and the University of Pennsylvania, including family-practice and family-nurse-practitioner qualifications. The company’s 2024 financing release identified her as chief clinical officer. Clinical services are delivered through independent provider-owned practices supported by Blackbird’s technology and administrative platform.

Anita Cattrell is president and chief operating officer of Blackbird Health, as identified in its March 2026 leadership announcement. Her historical Living Goods biography describes earlier healthcare innovation leadership at Evolent Health and monitoring and evaluation work with Partners In Health in Rwanda. It also documents clinical-epidemiology doctoral training and biomedical-engineering education at Harvard and Northwestern. Her authentic portrait is from a 2020 institutional report and is identified as historical.

Bethany Barney, MSS, LCSW, is published by Blackbird Health as a diagnostician and director of clinical evaluation. Her clinical-author biography describes specialization in neurodevelopmental disorders and child and adolescent mental health, with comprehensive assessments for children and families. The affiliation is source-qualified to the published clinical biography and current resource byline; direct employment by the management company is not inferred.

Caronne Taylor Bloom is published by Blackbird Health as an education advocate and licensed professional counselor. Her biography describes experience as a therapist and educator and interests including executive function, ADHD, tic disorders, autism, OCD, depression and school advocacy. The affiliation is published clinical-network work and educational authorship, without a management-company employment claim.

Coleen Vanderbeek is published by Blackbird Health as a clinician and writer on autism and early childhood, with its clinical-author biography identifying her as director of autism and early childhood. Her stated focus is neurodevelopmental behavioral health and comprehensive care for children. The role reproduces the public biography; an exact appointment date or independently verified employment arrangement is unavailable.

Gabrielle Derosier is published in Blackbird Health’s current clinical directory as a psychotherapist. Her listed areas include PTSD, anxiety, depression and sexual trauma, with an emphasis on supporting patients and their families. The clinical-network affiliation is distinguished from management-company employment.

Kevin Olivo, LCSW, is published by Blackbird Health as vice president of behavioral services. His responsibilities include clinical protocols, quality standards and organization-wide training to improve care delivery. His clinical leadership affiliation is distinguished from employment or supervision of licensed providers by the technology and management company.

Lucia Cortes is identified as a child and adolescent psychotherapist in Blackbird Health’s published patient story Confidence Comes Back. The source describes therapy and family support through its multidisciplinary model. The original story dates to 2024 and remains published; continued active clinical service and a current appointment date have not been independently established.

Matt Keener is a board-certified psychiatrist and co-founder of Blackbird Health. The company’s 2024 financing release describes his role in the 2021 relaunch alongside founder Amy Edgar. His self-published professional profile identifies child and adolescent and adult psychiatry training, neuroimaging research and a continuing co-founder affiliation. A current executive job at Blackbird is not inferred from his founder status.

Micah Munro is published in Blackbird Health’s current clinical directory as a psychotherapist. The directory names depression, anxiety, ADHD and OCD among her specialties. The affiliation is with the branded clinical network of independent medical practices; employment by Blackbird Health’s management company is not inferred.

Michael Tang joined Blackbird Health as chief medical officer on March 2, 2026. The organization describes him as board-certified in child and adolescent psychiatry, adult psychiatry, pediatrics and addiction medicine, with degrees from Harvard College, Harvard Medical School and Brandeis University. His published work concerns coordinated pediatric mental health care. Clinical oversight belongs to the independent provider-owned medical practices, rather than an assumed employment or supervisory relationship with the management company.

Molly Kotocavage is published in Blackbird Health’s current directory as an occupational therapist, with sensory processing and picky eating among the stated specialties. Her affiliation is with the branded independent clinical practice network. This directory entry is not treated as proof that every clinic currently delivers occupational therapy treatment.

Nicholas Mediate is published in Blackbird Health’s clinical directory as a psychotherapist, with family therapy and video-game addiction among his specialties. The company’s October 2026 resource byline also identifies him as manager of behavioral health. The role is an affiliation with the independent clinical-practice network, rather than an assumed employment relationship with the management company.

Nicole Garber formerly served as chief medical officer for Blackbird Health’s clinical network. The company’s March 2, 2026 announcement explicitly introduces her successor Michael Tang and describes her departure to focus on eating-disorder work and advocacy. Older resources still publish her author and medical-reviewer bylines; these are historical content rather than evidence that she remains chief medical officer.

Nikki Stone is published in Blackbird Health’s current clinical directory with the PMHNP-BC credential. Its listed specialties include anxiety, depression, mood disorders and PTSD. She is presented as part of the independent clinical practice network, without an assumed employment relationship with the management company.

Patrice Griffin is published in Blackbird Health’s clinical directory with an LPC credential and specialties including cognitive behavioral therapy, dialectical behavior therapy and trauma therapy. The current company page spells her surname Griffen, while its named original photograph and clinical-author biographies use Griffin; these sources identify the same pictured clinician. Her relationship is a branded clinical-network affiliation rather than assumed management-company employment.

Blackbird Health, Inc. is a Pittsburgh-based pediatric mental-health technology and administrative-services company supporting a network of independent provider-owned medical practices under the Blackbird brand. The original clinic was founded by Amy Edgar in 2014 and relaunched with psychiatrist and co-founder Matt Keener in 2021; the Delaware corporate entity was formed in 2021. Its understanding-first model integrates broad developmental, cognitive, emotional, behavioral and sensory assessments with individualized therapy, psychiatric support and family guidance for children, adolescents and young adults. The company’s 2024 release describes proprietary computational models and machine-learning algorithms applied to a longitudinal clinical dataset to identify symptom patterns and inform clinician-selected treatment; these are company-reported capabilities, not a claim of autonomous AI diagnosis, validated brain imaging or regulatory approval. Its current website advertises virtual and in-person services across Pennsylvania, Virginia, New Jersey and Maryland. A legal notice updated September 28, 2026 states that Blackbird itself does not provide medical care, own or operate practices, employ or supervise licensed providers; clinical care is the responsibility of Blackbird Clinical Services and other independent affiliated practices. Tom Peterson is CEO and Anita Cattrell is president and COO. Michael Tang joined as chief medical officer March 2, 2026, replacing Nicole Garber. The company announced an actual USD 17M SeriesA on February 21, 2024, led by Define Ventures with Frist Cressey Ventures and GreyMatter participating. The related SEC filing reports USD 22,770,022 of securities including debt conversion; that nominal total and nearly 23M cumulative funding are not additional fresh cash rounds. Distinct from the Blackbird venture-capital, restaurant-payments and narrative-intelligence companies.

Dan Nomura is named Investment Advisory Board in Droia’s current public directory. The published professional background includes Professor of Chemical Biology and Molecular Therapeutics at the University of California, Berkeley; Director of the Novartis-Berkeley Translational Chemical Biology Institute; Co-Founder of Frontier Medicines; Founder of Vicinitas Therapeutics. This is a manager-published affiliation; advisory-board membership and Droia Labs scientific roles are qualified separately from the investment team. Exact appointment dates and personal cash participation are not inferred.

Lord David Prior advises Automata on healthcare systems and institutional strategy. Previously chaired the Care Quality Commission and NHS England and served as a UK health minister. His existing Axiom affiliation is preserved; the current Automata advisory affiliation does not establish a personal investment.

Previously Senior Director of Business Development at Tempus AI; PhD in Biology and 15 years of oncology research and development at Pfizer. Leads commercial development for O-Predict and O-Target.

Ozi Amanat founded K2 Global in 2015 to invest in private technology companies. Its current issuer announcement identifies him as a solo venture capitalist.

LaevaCare develops physical support products for women’s pelvic-floor health after childbirth and for symptoms later in life. Its LaevaComfort support briefs and optional LaevaLift insert provide external compression and adjustable support. The company combines urogynecology, midwifery and engineering expertise and works with women and healthcare professionals on product testing and clinical studies. It sells products through its own webshop and develops clinical and retail partnerships.

Kiutra lists Carlo Germano Ravina in its Board and advisors directory as its NovaCapital representative. The directory does not specify a separate director or adviser title.

Midwife developing and testing pelvic-floor support products with postpartum women. Also published under the shortened name Eva Dimon.

Urogynecologist and obstetrician with more than40years of clinical experience in childbirth and pelvic-floor injuries. Leads LaevaCare’s medical foundations and product development.

Engineer working on LaevaCare’s prototypes, support mechanics, manufacturing quality and technical product development.

Registered nurse with marketing, commercialization and business-development experience; leads LaevaCare from clinical prototypes toward product sales.

LaevaCare publicly announced Viktoria as its first employee in April2026. Its earlier January update identified her communications internship and work writing pelvic-floor educational articles; a precise current employee job title is not published.

Kiutra develops helium-3-free cryogenic systems for quantum technologies. Its magnetic cooling technology uses controlled magnetization and demagnetization of solid-state materials to reach kelvin and millikelvin temperatures. The company supplies fast-feedback cryostats for testing quantum devices, modular cooling infrastructure for scalable quantum computers and optical cryostats for trapped-ion research, alongside sample-measurement services and laboratory access.

Bryan Cressey is co-founder & senior advisor at Frist Cressey Ventures. Healthcare private equity investor and company builder who co-founded FCV. Studied economics at Washington and law and business at Harvard.

Caroline Young is head of partnership development at Frist Cressey Ventures. Partnership leader at FCV since 2021. Previously helped launch NashvilleHealth and led the Nashville Health Care Council; has served on Cumberland Pharmaceuticals’ board.

Chloe Coulter is director of value creation at Frist Cressey Ventures. Joined FCV in 2023. Previously worked in human capital consulting at Deloitte and strategy, startup accelerators and innovation consulting at Innovator’s DNA.

Derek Dedeker is principal at Frist Cressey Ventures. Investor at FCV since 2022. Previously spent four years at Santé Ventures after working in financial institutions investment banking at Citi.

Harrison Frist is operating partner at Frist Cressey Ventures. Former CEO and founding team member of naviHealth, with earlier investing experience at Carlyle and banking experience at Goldman Sachs. Joined FCV as operating partner in April 2026.

J. Mark Tipps is partner & coo at Frist Cressey Ventures. Lawyer and organisational leader who joined FCV in 2023. Previously worked at Bass Berry & Sims and Walker Tipps & Malone and was Bill Frist’s Senate chief of staff.

Jamie Kuntz is associate, partnership development at Frist Cressey Ventures. Joined FCV in 2023, supporting communications, digital media and portfolio marketing. Previously coordinated programmes at Vanderbilt’s nanoscale science institute and taught English literature.

Lauren Martin is administrative assistant at Frist Cressey Ventures. Named on the firm’s current public team directory as administrative assistant. A detailed biography was not available from the accessible primary directory text.

Lydia Witty is investment associate at Frist Cressey Ventures. Investor at FCV since 2023. Previously a healthcare consultant at AArete and studied medicine, health and society at Vanderbilt.

Matt Schappell is principal at Frist Cressey Ventures. Healthcare investor at FCV since 2019. Previously in Ziegler’s healthcare technology investment banking group and business development at a Universal Health Services hospital.

Olivia Capra is partner at Frist Cressey Ventures. Healthcare investor previously at Kaiser Permanente Ventures and Convey Capital. Earlier supported Macro Trials and Cornerstone AI and covered specialty pharmaceuticals at Barclays.

Owen McGrath is director of finance and operations at Frist Cressey Ventures. Named on the firm’s current public team directory as director of finance and operations. A detailed biography was not available from the accessible primary directory text.

Tommaso Auerbach is senior associate at Frist Cressey Ventures. Investor at FCV since 2023, interested in AI and human health. Previously at Oxeon working on company creation, investing and executive search; studied at NYU.

Traci Few is manager, personnel and operations at Frist Cressey Ventures. Executive support and operations professional at FCV since 2021. Previously supported healthcare, property and legal executives, including at HCA and Parallon.

Whit Emerson is investment associate at Frist Cressey Ventures. Healthcare operator and investor previously on Monogram Health’s strategy team and the founding team of virtual cardiac wellness company Motiv. Earlier worked at Bright Health and EY-Parthenon.

William Trapnell is senior associate at Frist Cressey Ventures. Healthcare investor at FCV since 2021. Previously worked in Citi’s healthcare investment banking group and studied accounting at Tennessee.

Zach Johnson is chief financial officer at Frist Cressey Ventures. Finance professional at FCV since 2021. Previously an RSM tax manager advising investment funds; is a Tennessee CPA and studied accounting and finance at Marquette.

Zeena Johar is entrepreneur in residence at Frist Cressey Ventures. Healthcare entrepreneur who helped found Imagine Pediatrics and SughaVazhvu Healthcare. Previously led operations at Advantia Health and holds an ETH molecular diagnostics doctorate.

Duong Huynh is a published BrainCheck-affiliated cognitive-health research author. Peer-reviewed2025 studies document the company affiliation; a2026 job title or continued employment has not been inferred.

Kevin Sun is a published BrainCheck-affiliated cognitive-health research author. Peer-reviewed2025 studies document the company affiliation; a2026 job title or continued employment has not been inferred.

Liz Kwo is a physician appointed to BrainCheck’s board on January28,2026.

Yael Katz co-founded BrainCheck and formerly led it as CEO. The company’s own2019 review and2021 issuer financing release establish her founder role. Current operational employment is not assumed from historical biographies.

BSV Ventures, formerly Baltic Sandbox Ventures, invests at pre-seed and seed in research-intensive startups in the Baltics and wider Europe. It backs deep technology, life sciences, AI, robotics, advanced materials, computing, space, and defence or dual-use technologies as they move from scientific validation toward commercial products. The firm combines investment with incubation and acceleration programmes, business development, intellectual property and engineering support, and help building teams and international markets. Its fund management company is UAB BSV Management.

Nordic Science Investments is a Finnish venture capital manager backing university spinouts and early-stage science-based companies across the Nordic and Baltic region. It specialises in pre-seed commercialisation of research in deep technology, health technology and life sciences, including neuroplasticity drug development, AI-driven systems, semiconductors, advanced materials, and synthetic biology. The team works with universities and founders on technology transfer, business development, recruiting teams, strategic guidance, and later financing, with follow-on capacity through Series B. Its legal manager is Nordic Science Investments Oy; Taaleri acquired a51% ownership stake in April2026, while the founders retained operational roles.

Genetics PhD and former Stanford visiting researcher with experience in academic commercialisation, biotechnology R&D leadership, oncology, and digital health.

Supports business development and scaling portfolio companies beyond the seed stage.

Former investment banker and technology entrepreneur with experience structuring international transactions and founding and advising startups.

Analyses technology innovation, competitive differentiation, and industry applicability.

Focuses on engineering innovation, intellectual property strategy, complex technology sales, product and commercial strategy, team building, and early growth.

International finance and technology executive with experience in fundraising, public listings, exits, IoT, healthcare connectivity, AI, semiconductors, and business development.

Supports science-based business and growth projects while pursuing bioinformation technology and business administration studies at Aalto University.

Specialises in climate and sustainability technology, portfolio and fundraising support, and leading deals and portfolio work.

Supports marketing, communications, brand strategy, go-to-market planning, team design, ecosystem development, and portfolio companies.

Technology transfer and software entrepreneur experienced in creating and supporting university spinouts at Helsinki and Oxford. Leads Nordic Science Investments as CEO.

Supports science-based company sourcing, commercialisation, team development, and investment readiness. Previously led UniTartu Ventures and co-founded SEB Group’s Innovation Lab; serves on the EstVCA board.

Focuses on biotechnology, medical technology, AI and machine learning, early research and development, and strategy.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Published in Luminar’s operating-partner network.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Butterfly’s own current fund disclosure lists Henri Ailinpieti as Associate; its main team display omits him. The profile records the published disclosure role, with current employment requiring confirmation if the pages are inconsistent.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Published in Luminar’s operating-partner network.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Published in Luminar’s operating-partner network.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Published in Luminar’s operating-partner network.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Published in Luminar’s angel network. This network listing does not establish salaried employment or individual participation in every Luminar investment.

Published in Luminar’s operating-partner network.

Published in Luminar’s operating-partner network.

Butterfly Ventures is a Nordic and Baltic venture capital manager investing at pre-seed and seed in science-based deep technology, hardware and software connected to physical technology. It supports founders with product commercialisation, financing, partnerships and follow-on rounds, with offices in Finland, Sweden, Estonia and Denmark. Its portfolio spans industrial technology, energy, advanced computing, medical technology and AI, including brain-function monitoring company Cerenion and industrial AI support company Hypertype. Founded in 2012, Butterfly manages several venture funds and combines commercial growth with assessment of social and environmental impact.

Aoife Brennan is a Cerevance board director and Climb Bio’s president and chief executive officer. Her earlier career includes leadership at Synlogic and Biogen; she trained in medicine at Trinity College Dublin.

Brad Margus chairs Cerevance’s board and was its founding chief executive until 2022. He also founded and led Envoy Therapeutics and Perlegen Sciences, and established the A-T Children’s Project.

Campbell Murray is a Cerevance board director and co-founder and managing partner of Double Point Ventures. His prior investment roles include Bioluminescence Ventures, Agent Capital and Novartis Venture Fund. Campbell Murray joined Bioluminescence Ventures as Senior Partner in2024. Earlier he invested at Agent Capital and spent more than sixteen years at Novartis Venture Fund, and his operating experience includes Diabetes Free and Intima Bioscience. He trained in medicine at Auckland and earned Harvard business and public-policy degrees. His BLV appointment is historical: current Cerevance/DoublePoint sources identify his subsequent co-founder/managing-partner work at Double Point Ventures; those roles and authentic current portrait are preserved.

Caroline Quay is a Cerevance board director and managing partner of MQB Partners, a New Zealand biotechnology investor. Her healthcare investment experience includes medical devices, digital health, drug and biologic development, and diagnostics. She was Global General Counsel at Fisher & Paykel Healthcare and a founding executive of Aroa Biosurgery, which listed on the ASX in2020. She began her career in mergers and acquisitions, private equity and venture-investment law. She holds honours law and commerce degrees from the University of Auckland, received the EY/NZ Asian Leaders Scholarship for the University of Virginia Darden programme in2015, and was awarded the SBCWarburg finance scholarship. Earlier affiliations and public-company transactions are career history, distinct from current institutional checks.

Craig Thompson leads Cerevance as chief executive and serves on its board. His biotechnology and pharmaceutical career includes Neurana, Merck, Pfizer and Trius. This executive is distinct from cancer researcher Craig B. Thompson.

David Lubner is an independent director of Cerevance. His life sciences finance experience includes CFO positions at Ra Pharmaceuticals, Tetraphase, PharMetrics and ProScript.

Jeremy Nathans is a Johns Hopkins professor and HHMI investigator studying molecular mechanisms of neural development and visual function. Cerevance appointed him a scientific adviser in October 2017; his current advisory tenure has not been reconfirmed.

Johnna Simões leads corporate development at Cerevance. She previously worked in corporate development at Neurana and held biopharmaceutical strategy, business development and investor relations roles at Anthera and Trius.

Mark Carlton is Cerevance’s chief scientific officer, with experience spanning academic research and drug development. He co-founded Paradigm Therapeutics and previously led Takeda’s Cambridge UK research site as president and chief scientific officer.

Nicola Brice leads neuroscience at Cerevance. Her drug development work spans neurodegeneration, psychiatry and pain, from target selection through clinical studies. She trained at UCL and Oxford.

Nigel Ramsden leads drug discovery at Cerevance. His earlier industry experience includes GSK, Cellzome and RxCelerate, across multiple therapeutic modalities and stages of development.

Rob Middlebrook is Cerevance’s chief financial officer. His earlier roles include CFO of Envoy Therapeutics, corporate development leadership at Perlegen Sciences and senior investment management positions at Fidelity. Cerevance’s releases also identify him as Robert Middlebrook.

Rudolph Tanzi is a Harvard and Massachusetts General Hospital neuroscientist studying the genetics and biology of Alzheimer’s disease. Cerevance announced his scientific advisory appointment in October 2017; current tenure is unconfirmed.

Thomas Yonker leads operations at Cerevance. His biopharmaceutical project management career includes Neurana, Upjohn, Synergen, Abgenix and PaxVax.

Charlie Plauche appears in BrainCheck’s current Board of Directors & Advisors directory. Exact appointment date and the directory’s director-versus-adviser classification are not specified. Charlie Plauche joined S3 Ventures in 2010. The firm’s current team directory calls him Managing Director, while his individual biography calls him General Partner; both current public labels are retained. His portfolio board work includes BrainCheck, Cloverleaf AI, Interplay Learning and LeanDNA. Before S3 he worked at Harbert Private Equity Funds; he holds degrees from Mississippi and the University of Texas.

Xaviera Xiao is a published BrainCheck-affiliated cognitive-health research author. Peer-reviewed2025 studies document the company affiliation; a2026 job title or continued employment has not been inferred.

Bin Huang is BrainCheck Principal Scientist and the named principal investigator for its2025 NIH eConsult award. He earned a computational-biology PhD at Rice in2017 and works on cognitive assessments, cognitive-care planning and AI research.

Matthew (Matt) Cerullo’s published BrainCheck leadership-page biography identifies an April2022 Chief Revenue Officer appointment. His biography remains published but the current visible roster lacks a separate card; continued employment is not independently confirmed.

Stephen Bekanich is BrainCheck CMO, appointed March10,2026. A physician and Iris Healthcare co-founder, he previously held Aledade and Ascension roles. He studied medicine at Buffalo and trained at Utah.

Danny McPherson leads BrainCheck engineering, with previous Iris Healthcare and Aledade software-platform leadership. He studied computer science at the University of Texas.

Danielle Yoon leads BrainCheck marketing, with prior digital-pharmacy and enterprise-software experience. She studied communications and psychology at Boston University. Her directory heading says VP Marketing and biography describes Head of Marketing.

Andrew Chen leads a BrainCheck product program and previously co-founded Iris Healthcare, serving as Chief Product Officer and later Aledade VP Product. This Austin healthcare operator is distinct from the Andreessen Horowitz investor of the same name.

Elaine Cannizzaro leads BrainCheck operations after clinical-operations leadership at Iris Healthcare and a decade at Vital Decisions. She studied communication at William Paterson University and psychology and counseling at Goddard College.

Steve Wardle is BrainCheck President, appointed in July2025. He co-founded and led Iris Healthcare before its acquisition by Aledade, then served in Aledade practice-health leadership. He completed an MBA at Duke.

Robert Terrell leads product development at BrainCheck, drawing on healthcare, pharmacy and patient-engagement technology experience. He studied management information systems at the University of Louisiana at Lafayette.

Bassel Samman leads BrainCheck technology and information security, joining in2015. His work covers software, infrastructure and cybersecurity. He previously worked at Rackspace and studied computer science at UMass Amherst.

Judd Rabb is BrainCheck CFO and a certified accountant with technology-company finance experience, including OJO Labs, Digital Pharmacist, Main Street Hub, SolarBridge, Bazaarvoice and Silicon Laboratories. He studied accounting at Texas A&M.

Molly Penna leads customer success at BrainCheck, joining in2021. She has worked on healthcare-system implementations and Epic integration, following healthcare strategy work at Deloitte. She studied industrial engineering at the University of Miami.

Mary Patterson leads BrainCheck clinical and regulatory work, with neuroscience, Alzheimer’s and neurovascular trial experience. She studied neuroscience at Ohio University and aging and neuroscience at the University of South Florida.

Chris Loughlin leads BrainCheck as CEO, joining in October2024 after running Pixiu Investments and Digital Pharmacist and serving as Travelzoo CEO. He studied technology management and completed MBAs at Berkeley and Columbia.

BrainCheck, Inc. develops digital cognitive assessment and care software for healthcare providers. Its platform supports screening, structured cognitive assessments, longitudinal monitoring and personalized care planning for cognitive impairment, Alzheimer’s disease and related dementias. The company applies computational neuroscience and AI to scoring, clinical workflows, population analytics and research on earlier detection; funded projects include an AI companion for cognitive-care plans, AI assessment algorithms and an eConsult platform connecting primary-care clinicians with dementia specialists. BrainCheck Assess is identified by the company as an FDA Class II medical device intended for qualified healthcare-professional interpretation. It is not a standalone diagnostic device and does not establish the presence or absence of a clinical diagnosis. Screen, Plan and screeners are not regulated devices. Co-founders David Eagleman and Yael Katz established the business, and Chris Loughlin became CEO in October2024. Its current published leadership and scientific sources identify executives, directors, advisers and researchers, with historical or unverified current affiliations explicitly qualified. Verified financing includes an initial USD3 million raise, an aggregate USD8 million Series A whose earlier components are not counted again, USD10 million Series B in2021, USD15 million new financing in2024 and an additional USD13 million financing in February2026 that the issuer itself labels Series A. Research grants are recorded separately from venture funding, and inconsistent historical cumulative totals are not treated as new cash.

Scott Miller is venture partner at Next Coast Ventures, according to its current official roster. The firm’s published career biography records: EIR @ NCV | Co-Founder & VP Product @ TrustRadius | COO @ Vast (acq. Vroom) | Strategic Planning / APAC Ops @ SolarWinds | Austin Ventures | pcOrder / Trilogy Software | MIT BS + M.Eng, CSEE | HBS MBA. Outside executive and board references are reported as career history, with current status at each separate organisation not independently assumed.

Jason Dorsey is venture partner at Next Coast Ventures, according to its current official roster. The firm’s published career biography records: Gen Z and Millennial Expert | Global Keynote Speaker | 5x Author, 3x Founder | Led 70+ Research Studies | Corp Board Member | New book: Zconomy. Outside executive and board references are reported as career history, with current status at each separate organisation not independently assumed.

Cotter Cunningham is venture partner at Next Coast Ventures, according to its current official roster. The firm’s published career biography records: Consumer Internet and Marketplace Executive | Founder, Chair and CEO RetailMeNot (NASDAQ:SALE) | COO Bankrate (NASDAQ:RATE). Outside executive and board references are reported as career history, with current status at each separate organisation not independently assumed.

Julian Castelli is venture partner at Next Coast Ventures, according to its current official roster. The firm’s published career biography records: Senior Technology + SaaS executive | Serial entrepreneur with proven track record of delivering growth across multiple industries. Outside executive and board references are reported as career history, with current status at each separate organisation not independently assumed.

Brian Sharples is venture partner at Next Coast Ventures, according to its current official roster. The firm’s published career biography records: Co-founder and CEO of HomeAway | Member Board Of Directors at Avalara | Stanford University Graduate School of Business | Former President and CEO of IntelliQuest Information Group. Outside executive and board references are reported as career history, with current status at each separate organisation not independently assumed.

Atomontage develops Virtual Matter, a cloud-based volumetric computing and interactive 3D platform built on progressively streamed microvoxels. Its representation stores editable material volumes rather than only surfaces, allowing worlds and objects to be reshaped, destroyed, built and simulated while preserving changes. Creators can import meshes, photogrammetry and other scans, point clouds and volumetric datasets, then edit, remix and share them through a browser. The rebuilt 2026 platform adds optional AI agents for creating and modifying multiplayer games and persistent worlds, with instant play on mobile browsers and other devices. Beyond games and user-generated content, applications include archaeology, engineering and construction scans, underwater photogrammetry and biomedical imaging such as micro-CT and light-sheet microscopy. Founded in 2017 by Branislav Šíleš and Daniel Tabar, Atomontage is an active Makers Fund portfolio company.

GGWP develops an AI platform for content moderation, user safety and community intelligence. Built for high-volume live-service games, it now serves iGaming, virtual worlds, commerce, social communities, creator platforms, sports and education. Its platform detects policy violations across text, live voice, images, video, usernames, user reports and Discord, evaluates behavior over time, and automates policy-based actions such as warnings, mutes and bans. High-risk cases escalate to human reviewers, while a unified console provides incident review, policy controls and audit trails. GGWP also supplies community-health and sentiment analytics and managed human moderation. George Ng became CEO in September 2026, with co-founder Dennis Fong becoming Chairman. Makers Fund publishes GGWP as an active portfolio investment.

Adam Rogers is venture partner at Next Coast Ventures, according to its current official roster. The firm’s published career biography records: Former intern, CTO & CEO at Ultimate Software | Partner at Next Coast Ventures investing in & advising early-stage companies. Outside executive and board references are reported as career history, with current status at each separate organisation not independently assumed.

Atomontage co-founder and CEO, identified in the August 2026 interview linked and promoted by the company. Has developed the underlying voxel engine since 2004, drawing on a background in the demoscene.

Co-founded Atomontage in 2017. Game developer with experience creating Cortex Command and other interactive projects; the company’s August 2026 interview describes his role in rebuilding Virtual Matter with optional AI creation tools.

GGWP co-founder and Chairman, confirmed by the September 17, 2026 company announcement. Focuses on long-term strategy, business development and major partnerships after transitioning from the CEO role.

Co-founder and CEO of GGWP; appointed CEO on September 17, 2026 after serving as President and founding CTO. Previously co-founded Cyence and served as Chief Data Scientist at Cray; holds a PhD in economics from UC Irvine.

Named by GGWP’s September 17, 2026 release as one of its four co-founders alongside George Ng, Dennis Fong and Kun Gao. This records an enduring founder relationship; the company’s current staff and board directory does not publish a current operating title for him.

Paul Rogers is venture partner at Next Coast Ventures, according to its current official roster. The firm’s published career biography records: CTO at Equipment Share | Former CTO at RetailMeNot and Namely | Opened Google's Austin office in 2008 | Led the BazaarVoice engineering team during its start-up years. Outside executive and board references are reported as career history, with current status at each separate organisation not independently assumed.

Julie Dodd is venture partner at Next Coast Ventures, according to its current official roster. The firm’s published career biography records: Operating Partner at Welsh, Carson, Anderson & Stowe | Award-Winning COO & CSO | Former COO, CSO and General Manager at Ultimate Software. Outside executive and board references are reported as career history, with current status at each separate organisation not independently assumed.

Laura Schenke is operations consultant at Next Coast Ventures, according to its current official roster. The firm’s published career biography records: Operations Consultant at Next Coast Ventures. Former Nationally Board Certified Health & Wellness Coach at Noom | Assistant GM at Big Onion Tavern Group | General Manager & Event Coordinator at VIP Chicago Parties | MS from Concordia University | BS from Eastern Illinois University. Outside executive and board references are reported as career history, with current status at each separate organisation not independently assumed.

Kaitlyn DeBernardo is partner, coo & head of platform at Next Coast Ventures, according to its current official roster. The firm’s published career biography records: Stanford GSB MBA Grad | Early employee at Workrise (formerly RigUp) which raised over $700mm from their Series B to E funding rounds while she was there | Bank of America Merrill Lynch on the equity desk in New York | Stanford Graduate School of Business | Columbia University with a BA in Economics. Outside executive and board references are reported as career history, with current status at each separate organisation not independently assumed.

Thomas Ball is co-founder and managing director at Next Coast Ventures, according to its current official roster. Also named Charles Thomas Ball in the adviser’s legal filing. The firm’s published career biography records: Co-Founder & Managing Partner at Next Coast Ventures | On the Board of Aclaimant, UpEquity, Enboarder: Experience-Driven Onboarding, CoPilot, TrustRadius, GOJA, GoodKind Co, KLRU-TV | Former General Partner at Austin Ventures | Former Investor of Outbound Engineer, and Bazaarvoice | Founder of Tahoe Domains, Inc. | Former CEO/Founder of Razorgator/Openfield Technology | Former VP of Business Development at Lifeminders | Former CEO/Founder of eCoupons | Former Principal at Discovery Capital | Former Engagement Manager at Mitchell Madison Group | MBA from Stanford University Graduate School of Business | BS in Finance from University of Florida.. Outside executive and board references are reported as career history, with current status at each separate organisation not independently assumed.

Mike Smerklo is co-founder and managing director at Next Coast Ventures, according to its current official roster. Also known as Michael Arthur Smerklo in the adviser’s legal filing. The firm’s published career biography records: Co Founder & Managing Director at Next Coast Ventures | Author of Mr. Monkey and Me, A real survival guide for entrepreneurs | Crowdhealth Board Member | Everly Health Board Member | Street Smarts VR Board Member | Submittable Board Member | BrainCheck Board Member | Former CEO of ServiceSource (SREV) | Former Director of Business Development of Opsware | MBA, Northwestern University - Kellogg School of Management | BS, Miami University of Ohio. Outside executive and board references are reported as career history, with current status at each separate organisation not independently assumed.

Next Coast Ventures is an Austin-based venture capital platform founded in 2015 by experienced entrepreneurs Mike Smerklo and Thomas Ball. It invests in early and growth-stage technology companies in emerging markets between the US coasts and supports founders through operating experience, platform resources, venture partners and an expert network. Its portfolio includes artificial intelligence, enterprise software, robotics, digital healthcare and cognitive assessment, including BrainCheck, Diligent Robotics, Somite AI and Loman AI. The legal adviser is Next Coast Ventures, LLC, SEC exempt reporting adviser CRD 283699 / file 802-136396 in its April 30, 2026 Form ADV; named private funds and general partners are separate legal entities. The current published core roster comprises two investment leaders, two operations professionals and eight venture partners. The larger expert network comprises outside operators and advisers, rather than 150 employees of the firm. Historic outside employment and portfolio board lists may predate exits. The firm is distinct from North Coast Ventures. Own announcements confirm $85 million Fund I, $130 million Fund II and a March 2022 $310 million close split into $195 million Fund III, $50 million Select I and $65 million entrepreneurship-through-acquisition strategy. AUM, individual LP commitments, entrepreneurs sidecar assets and company cumulative funding are not additional cash closes.

Michael Gutch, also published as Mike Gutch, was appointed Chief Financial Officer of Noema Pharma in2022 and was named in its2023 financing announcement. Michael Samar is the company’s current CFO, appointed in2025. Gutch’s exact departure day is not established.

John Kemp is the neuroscience scientist expressly identified by Noema Pharma’s December2020 issuer announcement as its Chief Scientific Officer. The company names his contribution to its early scientific foundations. Current tenure, an exact appointment date and an original portrait are not independently established.

Luigi Costa co-founded Noema Pharma and served as CEO through its early clinical development and Series A/B financing. The issuer’s June2023 announcement states that Ilise Lombardo succeeded him after he stepped down to pursue other opportunities. The exact departure day is not independently established.

Ali Mostajelean is a Noema Pharma scientific advisor and UCSF pediatric neurologist specializing in epilepsy. The company describes his clinical epilepsy and tuberous-sclerosis work at UCSF Benioff Children’s Hospital Oakland. UCSF’s own current provider directory corroborates his identity and supplies an authentic portrait.

Andreas Hartmann is a Noema Pharma scientific advisor. The issuer’s2021 Tourette study announcement identifies him as a clinical expert at Sorbonne University and Pitié-Salpêtrière Hospital in Paris. This neurologist is distinct from similarly named management consultants, hydrology researchers and mathematical physicists. An authentic original portrait is not independently verified.

Gerald Maguire is a Noema Pharma scientific advisor and a psychiatrist known for research on the medical treatment of stuttering. His published career includes psychiatry and neuroscience at UC Riverside and earlier academic work at UC Irvine. His UCR portrait is a genuine historical university image; it does not independently establish a current faculty appointment.

Tanjala Gipson is a Noema Pharma scientific advisor and pediatric neurologist. Her hospital’s current directory identifies her as director of its TSC-associated neuropsychiatric disorders clinic and a University of Tennessee Health Science Center professor in developmental pediatrics. Her clinical interests include tuberous sclerosis and neurodevelopmental disabilities.

Terence Coderre is a Noema Pharma scientific advisor and a McGill pain researcher. McGill’s primary directory identifies him as Harold Griffith Professor in Anesthesia Research. His work examines neuronal pain mechanisms and neuroplasticity in the spinal cord and brain.

Felice Verduyn-van Weegen is a Noema Pharma board member and an EQT Life Sciences partner. The company’s biography describes earlier work at LSP before its integration into EQT, and prior consulting at McKinsey. Noema’s December2024 extension announcement confirms her board appointment alongside EQT’s institutional investment.

Catherine Moukheibir is a Noema Pharma board member. Her career includes biotechnology board service, pharmaceutical management and finance, including previous leadership at MedDay Pharmaceuticals and Innate Pharma. The other board affiliations listed in her company biography are retained as published career context rather than independently asserted as current.

Arthur Franken is a Noema Pharma board member and is described by its published biography as a Gilde Healthcare general partner and founding-team member who joined in2001. His investment work includes biopharmaceuticals, medical technology, diagnostics and digital health. Gilde’s corporate investment is distinct from board membership or a personal check.

Darren Carroll is a Noema Pharma board member. Its biography describes his partnership at Polaris Partners from2020 and a prior22-year career at Eli Lilly, including leadership of global business development. Polaris’s institutional Noema investments are distinct from any personal holding.

Mehdi Ainouche is a Noema Pharma board member. Its published biography identifies him as a Jeito Capital partner with life-sciences investment experience across ophthalmology, oncology, CNS, cardiometabolic and neuromuscular conditions. His board membership does not by itself establish a personal investment in Noema. Mehdi joined Jeito Capital, a global leading independent Private Equity fund, with €534 million under management based in Paris and New York in 2020, following the launch of the fund, and was involved in several investments and portfolio companies notably in the fields of neurology, ophthalmology, oncology, cardiometabolic, neuromuscular diseases and fibrosis.  Prior to Jeito, Mehdi's last role was Associate within the healthcare venture team of Turenne Capital, a French investment group with over €1.8 billion under management, where he successfully participated to several investments in biotech & medtech. Mehdi holds a Pharmacy Doctorate from University of Rennes (France) and a Master in Business from ESCP Europe Business School Paris. Mehdi Ainouche is Jeito Capital’s current Partner. Joined 2020, became Partner 2025 following Principal and Senior Principal roles. Former Turenne healthcare investor; Rennes pharmacy doctorate and ESCP business masters.

Jeffrey Jonas is Chairman of Noema Pharma’s board. A neuroscience biotechnology executive, he served as Chief Executive Officer of Sage Therapeutics from2013 to2020 and previously held pharmaceutical leadership roles including at Shire. Older statements in Noema’s biography about subsequent Sage positions are historical context rather than independently reconfirmed current employment.

Michel David is Noema Pharma’s Vice President of CMC and Clinical Supply. His background includes pharmaceutical manufacturing, development, end-to-end supply-chain management and external-provider partnerships, with prior responsibilities at Roche. He is distinct from Montara physician David Michelson and Anzu investor David Michael; an image filename spelling Michael does not change the published Michel identity.

Sally Nixon is Noema Pharma’s Head of Operations. She has pharmaceutical-development and program-management experience spanning scientific, technical and business functions. Her earlier roles include senior program leadership at Certara and global medical-affairs project management at Roche.

Robert Lasser, also published as Rob Lasser, is Noema Pharma’s Chief Medical Officer. His CNS development experience includes clinical practice, research and biotechnology leadership. Previously he worked at Sage Therapeutics on zuranolone development and served as Chief Medical Officer at MedDay Pharmaceuticals. The company’s2023 appointment release uses Robert; its current directory uses Rob.

Michael Samar is Noema Pharma’s Chief Financial Officer. His earlier roles include CFO at Windgap Medical and Assembly Biosciences, finance leadership at Acorda/Biotie, Onyx, Agennix and Johnson & Johnson pharmaceutical research. He holds an MBA from Villanova University and a finance degree from Bryant University. His experience with other companies’ capital raises is distinct from Noema’s funding.

Volker Knappertz is Noema Pharma’s Executive Vice President of Research and Development. His career includes research leadership at Aurinia Pharmaceuticals and GW Pharmaceuticals, with experience advancing investigational medicines through development and regulatory review. Prior approvals mentioned in his biography concern other companies’ medicines and do not establish approval of Noema’s investigational candidates.

Ilise Lombardo is Noema Pharma’s Chief Executive Officer and a board director. She became CEO in June2023 after joining the board in2021. A physician and CNS drug-development executive, she co-founded Arvelle Therapeutics and served as its Chief Medical Officer before its acquisition by Angelini Pharma. Her earlier work includes Kriya Therapeutics, Pfizer, Forum and Axovant, and academic research at Columbia. She trained in psychiatry, neuroreceptor imaging and molecular genetics.

Noema Pharma AG is a Basel clinical-stage biotechnology company developing oral small-molecule therapeutics for neurological and related disorders. Sofinnova Partners seed-financed its formation in 2019, and the company licensed four clinical-stage assets from Roche. Its current pipeline focuses on two programs: basimglurant (NOE-101), an mGluR5 negative allosteric modulator for trigeminal neuralgia, and cendifensine (NOE-115), a broad-spectrum monoamine modulator for menopause-related vasomotor and other symptoms. The website labels basimglurant Phase 2/3 and reports an FDA Fast Track designation; the candidates remain investigational. Earlier announcements described additional studies in tuberous sclerosis complex, Tourette syndrome and childhood-onset fluency disorder, which are retained as historical development context rather than assumed to remain the current pipeline. Noema’s public directory contains six executives, nine board seats and five scientific advisors, representing19 distinct people. Ilise Lombardo leads the company as CEO and director. Noema closed a CHF54M Series A in December2020 and a CHF103M Series B in March2023. Its December2024 extension brought the total Series B round to CHF130M; this is not a separate CHF130M cash raise. The independent Swiss Venture Capital Report2025 directly reports CHF27M for the2024 extension; the issuer itself published the CHF130M aggregate rather than a separate incremental amount. The2019 seed amount remains undisclosed. Roche’s original shareholding was consideration for licensed assets, distinct from a proved cash investment.

Martin Rosenzweig is publicly listed as an advisor to GreyMatter Capital. The manager’s own directory describes the professional background as: Behavioral Chief Medical Officer, Optum. This directory caption describes outside affiliations and experience; it does not establish current employment at those organizations or a GreyMatter executive position.

Devika Bhushan is publicly listed as an advisor to GreyMatter Capital. The manager’s own directory describes the professional background as: Pediatrician, public health leader, and former Acting Surgeon General of California. This directory caption describes outside affiliations and experience; it does not establish current employment at those organizations or a GreyMatter executive position.

Pete Shalek is publicly listed as an advisor to GreyMatter Capital. The manager’s own directory describes the professional background as: CPO AbleTo, Co-Founder & CEO, Joyable. This directory caption describes outside affiliations and experience; it does not establish current employment at those organizations or a GreyMatter executive position.

Giovanni Colella is publicly listed as an advisor to GreyMatter Capital. The manager’s own directory describes the professional background as: Co-founder, CEO Vanna Health, Ooda Health, Castlight Health; Co-founder, Brightline. This directory caption describes outside affiliations and experience; it does not establish current employment at those organizations or a GreyMatter executive position.

Tyler Norris is publicly listed as an advisor to GreyMatter Capital. The manager’s own directory describes the professional background as: Former CEO, Well Being Trust. This directory caption describes outside affiliations and experience; it does not establish current employment at those organizations or a GreyMatter executive position.

Kacie Kelly is publicly listed as an advisor to GreyMatter Capital. The manager’s own directory describes the professional background as: Chief Innovation Officer, Meadows Mental Health Institute (GreyMatter Policy Partner). This directory caption describes outside affiliations and experience; it does not establish current employment at those organizations or a GreyMatter executive position.

Richard Park is publicly listed as an advisor to GreyMatter Capital. The manager’s own directory describes the professional background as: Co-founder & former CEO, CityMD; Co-founder, Ascend Partners.. This directory caption describes outside affiliations and experience; it does not establish current employment at those organizations or a GreyMatter executive position.

Kelly Clark is publicly listed as an advisor to GreyMatter Capital. The manager’s own directory describes the professional background as: Former President, American Society of Addiction Medicine. This directory caption describes outside affiliations and experience; it does not establish current employment at those organizations or a GreyMatter executive position.

Margaret Laws is executive in residence at Hopelab and The Omidyar Group, supporting partners and investees and exploring mental-health innovation. She was Hopelab’s president and CEO from 2015 to 2025. At the California HealthCare Foundation she held public-financing and innovation leadership positions and launched its Health Innovation Fund. GreyMatter Capital also publicly lists her as an advisor; its older Hopelab CEO caption describes her former role.

Patrick Kennedy is publicly listed as an advisor to GreyMatter Capital. The manager’s own directory describes the professional background as: Leading mental health advocate and co-author of Mental Health Parity Act. This directory caption describes outside affiliations and experience; it does not establish current employment at those organizations or a GreyMatter executive position.

Martha Temple is publicly listed as an advisor to GreyMatter Capital. The manager’s own directory describes the professional background as: Former CEO, Optum Behavioral Health. This directory caption describes outside affiliations and experience; it does not establish current employment at those organizations or a GreyMatter executive position.

Dena Bravata is publicly listed as an advisor to GreyMatter Capital. The manager’s own directory describes the professional background as: Co-founder & former CMO, Lyra CMO, Castlight Health. This directory caption describes outside affiliations and experience; it does not establish current employment at those organizations or a GreyMatter executive position.

Founding Partner of GreyMatter Capital. Before GreyMatter, he worked with mental-health startups and nonprofits, co-founded independent-work platform Prefer and served as its COO. Earlier he invested at Institutional Venture Partners and worked in technology investment banking at Qatalyst Partners. His current biography describes participation in San Francisco General Hospital Foundation’s behavioral-health transformation committee and earlier Well Being Trust advisory work. He studied economics and philosophy, politics and economics at the University of Pennsylvania.

Venture Partner at GreyMatter Capital with experience in venture investing and healthcare technology. Her published biography describes strategic payer partnerships at Grow Therapy and earlier investing at General Catalyst, where she directed university-founder program Rough Draft Ventures. She previously supported platforms and portfolio development at Redpoint and Eniac Ventures. She earned a Harvard education master’s degree and studied psychology and communications at the University of Pennsylvania. Prior-employer investments are not attributed to GreyMatter.

Carrie Milby is named in Cohere Health’s dated SEC filing. The role is retained as a historical or last-confirmed affiliation; current status and departure date are not established.

Duncan Reece is named in Cohere Health’s dated primary SEC and/or issuer history. The role is retained as a historical or last-confirmed affiliation; current operating status and departure date are not established. Duncan’s name is misspelled Reese in the2021 SEC filing but issuer profile names Reece.

Kristen Carucci is named in Cohere Health’s dated SEC filing. The role is retained as a historical or last-confirmed affiliation; current status and departure date are not established.

William H. Shrank is named in Cohere Health’s dated SEC filing. The role is retained as a historical or last-confirmed affiliation; current status and departure date are not established.

David Barrett is identified as a Cohere Health director in the company’s May2025 SEC Form D. This source confirms a dated corporate board affiliation, not an individual cash investment or additional operating role. David (Dave) Barrett is Polaris’ senior advisory partner in Boston and a managing partner of Funds VI–IX and the Healthcare Technology Opportunities Fund. His healthcare AI interests include care-management platforms; Polaris confirms his Cohere Health board seat. Earlier operating experience includes Calico, Pure Atria/Rational and Lotus.

Julian Harris is identified as a Cohere Health director in the company’s May2025 SEC Form D. This source confirms a dated corporate board affiliation, not an individual cash investment or additional operating role.

Michael Greeley is identified as a Cohere Health director in the company’s May2025 SEC Form D. This source confirms a dated corporate board affiliation, not an individual cash investment or additional operating role. Michael Greeley is co-founder and general partner of Flare Capital Partners, previously founding general partner at Flybridge and earlier with Polaris Partners, Wasserstein Perella and Morgan Stanley. His own manager biography explicitly includes Cohere Health among board seats and lists a Williams chemistry BA and Harvard MBA.

Paul Johnson is an orthopedic spine surgeon with30+ years of experience who joined Cohere Health’s medical advisory board in April2025. The company identifies his participation in early spine clinical pathways and membership of the American Academy of Orthopaedic Surgeons and North American Spine Society. He advises clinical policies; this is not a corporate director or individual investment role.

Gary L. Gottlieb is executive chair of Cohere Health, explicitly identified by the company’s February2026 board-appointment release. Its2025 founders interview and SEC2025 filing corroborate his chair/director identity. Further career history is preserved if already recorded; no quoted chair role implies personal investment.

Mark Leenay joined Cohere Health’s board in February2026. A board-certified family-medicine/geriatrics physician, he previously served as COO of ChenMed, CEO of InHealth MD Alliance, and EVP/CMO of WellCare, and held executive positions at UnitedHealth Group. He earned his MD at Thomas Jefferson University.

Robert (Bob) Shepardson became Cohere Health CFO in October2024, with35+ years in healthcare and technology finance. The issuer cites his Princeton economics degree and Dartmouth Tuck MBA. SECMay2025 also names him executive officer and secretary.

Sohail Djariri was appointed Cohere Health chief revenue officer in April2026. Previously chief growth officer at Sagility, he spent17 years at Cognizant expanding its healthcare/life-sciences practice and also served in an executive role at Wipro.

Cathy Fackovec joined Cohere Health in January2026 to lead clinical and service operations. She has30+ years of clinical leadership and healthcare operations experience, with prior senior utilization-management/clinical-operations and market-president roles at naviHealth and Tomorrow Health.

Gigi Yuen-Reed, also published as Gigi Yuen, is Cohere Health’s chief data and AI officer, leading data management, data science, machine learning/AI and business intelligence. The company’s June2026 release confirms her PhD and recognition on its100 Women in AI2026 list.

Brian Covino is Cohere Health’s chief medical officer and an orthopedic surgeon with25+ years of clinical experience. Previously partner at Knoxville Orthopaedic Clinic and value-based care leader at OrthoTennessee, he earned a Harvard bachelor’s and Georgetown MD/MS, trained at Virginia and completed a Cleveland Clinic fellowship.

Siva Namasivayam co-founded Cohere Health and has served as CEO since2019. Previously a founding partner of SCIO Health Analytics, he has20+ years of healthcare technology and data experience. He holds a computer-science master’s from Pittsburgh and an MBA from Michigan.

Liana Nunziato is Senior Director of Commercial Strategy at Cohere Health, listed on its current growth client experience department page. The company recognizes this employee for cross-team collaboration and contributions to its healthcare technology and operations. A detailed education and prior-career biography was not published on this source.

Ryan Hebert is Client Support Specialist - L2 Triage at Cohere Health, listed on its current growth client experience department page. The company recognizes this employee for cross-team collaboration and contributions to its healthcare technology and operations. A detailed education and prior-career biography was not published on this source.

Nicole Saidai is Manager of Client & Provider Training and Development at Cohere Health, listed on its current growth client experience department page. The company recognizes this employee for cross-team collaboration and contributions to its healthcare technology and operations. A detailed education and prior-career biography was not published on this source.

Jayd Keener is Lead RN Reviewer at Cohere Health, listed on its current clinical operations strategy programs department page. The company recognizes this employee for cross-team collaboration and contributions to its healthcare technology and operations. A detailed education and prior-career biography was not published on this source.

Danielle Williams is RN Reviewer at Cohere Health, listed on its current clinical operations strategy programs department page. The company recognizes this employee for cross-team collaboration and contributions to its healthcare technology and operations. A detailed education and prior-career biography was not published on this source.

Ashleigh Magill is Associate Medical Director, Utilization Management at Cohere Health, listed on its current clinical operations strategy programs department page. The company recognizes this employee for cross-team collaboration and contributions to its healthcare technology and operations. A detailed education and prior-career biography was not published on this source.

Tina Hunt is Intake Specialist at Cohere Health, listed on its current clinical operations strategy programs department page. The company recognizes this employee for cross-team collaboration and contributions to its healthcare technology and operations. A detailed education and prior-career biography was not published on this source.

Sharika Gary is Real Time Analyst and Scheduler at Cohere Health, listed on its current clinical operations strategy programs department page. The company recognizes this employee for cross-team collaboration and contributions to its healthcare technology and operations. A detailed education and prior-career biography was not published on this source.

Josh Gallatin is Senior Strategic Operations Analyst at Cohere Health, listed on its current clinical operations strategy programs department page. The company recognizes this employee for cross-team collaboration and contributions to its healthcare technology and operations. A detailed education and prior-career biography was not published on this source.

Fatima Naqvi is Intake Specialist at Cohere Health, listed on its current clinical operations strategy programs department page. The company recognizes this employee for cross-team collaboration and contributions to its healthcare technology and operations. A detailed education and prior-career biography was not published on this source.

Daniel Torres is Clinical Training and Quality Specialist at Cohere Health, listed on its current clinical operations strategy programs department page. The company recognizes this employee for cross-team collaboration and contributions to its healthcare technology and operations. A detailed education and prior-career biography was not published on this source.

Emily Bliss is Medical Policy Writer at Cohere Health, listed on its current clinical operations strategy programs department page. The company recognizes this employee for cross-team collaboration and contributions to its healthcare technology and operations. A detailed education and prior-career biography was not published on this source.

Alaura Shefchik is Senior People Business Partner at Cohere Health, listed on its current ga department page. The company recognizes this employee for cross-team collaboration and contributions to its healthcare technology and operations. A detailed education and prior-career biography was not published on this source.

April Furlong is Compliance Project Manager at Cohere Health, listed on its current ga department page. The company recognizes this employee for cross-team collaboration and contributions to its healthcare technology and operations. A detailed education and prior-career biography was not published on this source.

Zoe Liao is Data Scientist II at Cohere Health, listed on its current technology department page. The company recognizes this employee for cross-team collaboration and contributions to its healthcare technology and operations. A detailed education and prior-career biography was not published on this source.

Tommy Sully is Senior Product Manager - AI Platform and Review AI at Cohere Health, listed on its current technology department page. The company recognizes this employee for cross-team collaboration and contributions to its healthcare technology and operations. A detailed education and prior-career biography was not published on this source.

Saikrishna Jaliparthy is Lead Software Engineer at Cohere Health, listed on its current technology department page. The company recognizes this employee for cross-team collaboration and contributions to its healthcare technology and operations. A detailed education and prior-career biography was not published on this source.

Kenji Fujita is Staff AI Platform Engineer at Cohere Health, listed on its current technology department page. The company recognizes this employee for cross-team collaboration and contributions to its healthcare technology and operations. A detailed education and prior-career biography was not published on this source.

Richard Lu is Product Designer at Cohere Health, listed on its current technology department page. The company recognizes this employee for cross-team collaboration and contributions to its healthcare technology and operations. A detailed education and prior-career biography was not published on this source.

Caterina Wang is Software Engineer II at Cohere Health, listed on its current technology department page. The company recognizes this employee for cross-team collaboration and contributions to its healthcare technology and operations. A detailed education and prior-career biography was not published on this source.

Anna Wang is Software Engineer II AI Platform at Cohere Health, listed on its current technology department page. The company recognizes this employee for cross-team collaboration and contributions to its healthcare technology and operations. A detailed education and prior-career biography was not published on this source. Principal at GreyMatter Capital with experience in private-market investing and startup operations. Previously Director of Strategic Partnerships at Blueprint Power, she worked on energy technology following its acquisition by BP. Earlier she invested in venture funds, growth equity and renewable-energy infrastructure at CPP Investments and worked in technology investment banking at TD Securities. She studied finance and strategy at McGill University. Her historical infrastructure investment totals are not GreyMatter capital.

Cohere Health Inc. is a Boston-based healthcare AI company whose clinical intelligence and operations platform connects health plans and providers across utilization management, prior authorization, payment integrity, appeals, care management and quality measurement. Cohere Unify combines clinician-developed policies with domain-specific machine learning and agentic AI to extract clinical evidence, automate appropriate approvals, guide review and improve workflow coordination. The company says that AI is used to support approvals and that non-approved requests are reviewed by licensed medical professionals; reported approval, savings, ROI and satisfaction metrics are issuer claims, not independently established clinical outcomes. It was incubated with Define Ventures and Humana in2019, with Siva Namasivayam as co-founder and CEO. Its public department pages name21 staff, alongside current and dated executive/medical advisory and corporate board affiliations; this is not a complete700-plus employee directory. The company is relevant to healthcare AI, clinical decision automation and insurance workflow technology, not a documented neural-interface or neuroscience therapeutics developer. It is distinct from Canadian language-model company Cohere/cohere.com, Cohere Technologies, cohere-tech.com and Cohere Capital. Primary financing releases report USD10M Series A July16,2020, an additional USD10M Series A extension in October2020, USD36M Series B April13,2021, USD50M additional equity February1,2024 and USD90M Series C May14,2025. The October2020 own-site date is October22 versus the distributed issuer release October21; the own dated report is used. The2021 release says three months after an Aextension despite the surviving October2020 release: no inventedJanuary2021 additional cash. SEC equity amounts are same-event disclosure snapshots, not extra rounds:36,099,972 in2021;39,999,987 in2024 versus issuer50M event;89,999,876 in2025 versus rounded90M. The issuer’s2025 cumulative200M differs from summed published event values196M; the unexplained difference is not added as an imagined financing. Current medical/governance roles and older dated affiliations are explicitly qualified; directors/advisers are not assumed individual investors.

Amanda D. Huelskamp joined the Kansas insurer’s board in 2020 and serves on its compensation committee. The insurer’s biography identifies her as an HR business partner for enterprise initiatives at VSE Corp., with business and operations-management education at Wichita State University. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

Angela N. Wilson, DDS, joined the Kansas insurer’s board in 2018, chairs its dental advisory committee and serves on compensation and governance committees. Her individual biography describes her periodontal private practice at Southwind Periodontics; the general roster uses Edwards & Wilson Periodontics. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

Brittni Oehmke joined the Kansas insurer’s board in 2024 and serves on its investment committee and chairs its hospital advisory committee. She has led Hanover Hospital as CEO and administrator since August 2016. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

Garrett Love joined the Kansas insurer’s board in 2023 and serves on finance, investment and audit/compliance committees. He founded Love Land & Cattle and is also publicly listed on the insurer foundation’s board. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

James A. Klausman was elected to the Kansas insurer’s board in 2015 and serves on compensation and investment committees. He is CEO and co-founder of Midwest Health, a senior-living operator founded in 1977. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

Jeff D. Mullen joined the Kansas insurer’s board in 2018 and chairs its finance committee. He also serves on governance, investment and audit/compliance committees and is president of Ritchie Development. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

Jeffrey R. Thompson joined the Kansas insurer’s board in 2017 and chairs its audit/compliance committee. The individual biography identifies him as CFO of Velocity Flow Technologies, formerly Salina Vortex; the general roster retains the earlier company name. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

Jena K. Lysen joined the Kansas insurer’s board in 2017 and chairs its compensation committee. Her individual biography identifies her as human-resources director at Martin, Pringle, Oliver, Wallace & Bauer. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

Megan L. Jones joined the Kansas insurer’s board in 2016 and is its current board chair. She chairs the governance and investment committees and founded Jones Advisory Group, where she develops clients’ financial strategies. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

Rick C. Jackson was elected to the Kansas insurer’s board in 2015. He serves on governance, finance and audit/compliance committees, bringing banking and regulatory-compliance experience associated with Capitol Federal. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

Gregory V. Binns joined the Kansas insurer’s board in 2016 and serves on finance and audit/compliance committees. His current biography describes him as retired vice chairman of First National Bank of Hutchinson. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

James H. Gilbaugh III, MD, joined the Kansas insurer’s board in 2022 and serves on investment and medical advisory committees. He practices reproductive medicine and trained at Oregon Health Sciences University. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

Leonard R. Hernandez joined the Kansas insurer’s board in 2012 and serves on its compensation committee. Its individual biography identifies him as a retired hospital executive, most recently president and CEO of Susan B. Allen Memorial Hospital. A broader board listing retains an older South Central Kansas Health affiliation. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

Rick D. Baden joined the Kansas insurer’s board in 2020 and serves on its finance and audit/compliance committees. The insurer’s biography identifies him as Watco’s executive vice president and CFO and a certified public accountant. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

Sunee Mickle leads government and community relations at Blue Cross and Blue Shield of Kansas, holding the vice president appointment since April 2018. She joined in 2007 after policy and healthcare-industry roles. She studied public health at Rutgers and law at Washburn University. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The authentic named insurer-blog photograph is historical, not claimed as a newly taken portrait.

Clay Britton is senior vice president, general counsel and corporate secretary of Blue Cross and Blue Shield of Kansas. He joined in December 2021 and received the senior vice president appointment in 2023. His prior work includes counsel to Kansas Governor Laura Kelly, federal prosecution and private legal practice. He studied law at the University of Kansas. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

Holly Graves is vice president of operations and COO of government programs at Blue Cross and Blue Shield of Kansas, holding that role since 2020. She joined as a claims examiner in 1985 and subsequently led service and operational teams, including administration of federal healthcare programs. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

Mandy Harris became chief of staff at Blue Cross and Blue Shield of Kansas in 2024. She began with the insurer as a New Venture Initiative intern, later working on enterprise risk, strategy and analytics. She studied accounting at the University of Idaho and earned an MBA at the University of Kansas. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

Matt Langdon leads information technology as vice president and CIO of Blue Cross and Blue Shield of Kansas, a role held since 2020. He joined the insurer in 1997 and previously worked in enterprise architecture and systems analysis. He earned a business-administration degree at Washburn University. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

Mike Gerrish leads marketing and customer experience at Blue Cross and Blue Shield of Kansas, having joined in 2020. His earlier experience includes Wellmark Blue Cross Blue Shield, Payless ShoeSource and Discover Financial Services. He studied communications at Western Illinois University. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

Nicki Flanagan leads human resources at Blue Cross and Blue Shield of Kansas as senior vice president and chief human resources officer, with the senior appointment confirmed since 2023. She joined the insurer in 2016, following operational and HR leadership at The Home Depot’s supply-chain business. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

Raelene Knolla, DO, was appointed senior vice president and chief medical officer at Blue Cross and Blue Shield of Kansas in 2025. Her prior roles include Medrina, Blue Cross and Blue Shield of Kansas City and Humana. She trained in osteopathic medicine and healthcare management. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

Treena Mason is executive vice president and chief sales officer at Blue Cross and Blue Shield of Kansas, holding the current appointment since 2023. She joined in 1997 and progressed through regional sales, marketing and operational leadership. Her publicly listed outside service includes the Wichita Chamber of Commerce and Wichita State University’s business-school advisory board. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The authentic named insurer-blog photograph is historical, not claimed as a newly taken portrait.

Blue Cross and Blue Shield of Kansas, Inc. is a Kansas member-owned, not-for-profit mutual health insurer based in Topeka and an independent licensee of the Blue Cross Blue Shield Association. Its exact current corporation was formed May 1, 1983 through consolidation of the earlier Kansas Blue Cross and Blue Shield organizations; predecessor health-insurance operations began in March 1942. It serves 103 Kansas counties, excluding Johnson and Wyandotte, and is distinct from Blue Cross and Blue Shield of Kansas City, other regional Blue plans and the separately incorporated Kansas foundation. The insurer supports healthcare innovation through corporate strategic investments and its historically documented New Ventures Initiative. Its CFO’s current own biography explicitly includes responsibility for strategic investments. It invested USD1.5 million in teen behavioral-health technology company BeMe Health in an issuer announcement dated November 14, 2023, accompanying a mental-health access partnership. This establishes a healthcare and behavioral-health technology investment relationship, not a claim that the insurer itself develops AI or neuroscience devices. The current public leadership directory names twelve executives and its governance roster names fifteen directors, with Matthew D. All appearing in both. All is president and CEO, and Megan L. Jones is board chair. The current individual director biographies take precedence where the summary roster retains an older external-employer name. The organization has no capital-stock authority under its own articles; policyholder premiums, investment assets, statutory reserves, charitable grants and foundation gifts are not represented as venture-fund closings or company equity raises. No separately verified limited-partnership venture vehicle or public closed-fund capital allocation has been established. The authentic corporate logo is from its own public blog. Three named authentic historical portraits were retrievable from that blog; other current leadership image endpoints are publicly published but their binary files were unavailable, and those gaps remain explicit. BeMe’s August 2024 additional financing announcement does not name Kansas, so no second participation is inferred.

Jeff Bergman is the Kansas insurer’s senior vice president and CFO, overseeing accounting, actuarial work, risk management, underwriting, strategic investments and vendor management. He joined the organization in 2007 as an actuarial analyst and became senior vice president in 2023. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

Matthew D. All leads Blue Cross and Blue Shield of Kansas as president and CEO, a position held since April 2018. He joined the insurer in 2006 and previously served as its general counsel. His earlier public-service work included Kansas insurance regulation and legal counsel to Governor Kathleen Sebelius. He earned his undergraduate degree at the University of Kansas and law degree at Yale. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The authentic named insurer-blog photograph is historical, not claimed as a newly taken portrait.

Staci Berger leads provider-network solutions at Blue Cross and Blue Shield of Kansas, with the current appointment confirmed since 2024. Her work involves network programs, provider collaboration and access to care. Her earlier healthcare experience includes UnitedHealthcare and Humana. Current role and career details are confirmed in the insurer’s own public biography. External affiliations are biographical context; no outside organization roles or personal investment checks are inferred. The insurer publishes a leadership image endpoint, but a matching binary portrait was not retrievable; no substitute photograph is used.

Dennis Moreno leads manufacturing and operations at MiRus. His engineering background spans aerospace projects, robotics and medical-device development; his current individual biography and leadership directory agree on this operational role despite an older engineering title in the URL.

Wayne Gray leads orthopedic engineering at MiRus. His career includes research and development for orthopedic, spinal and extremity products at Zimmer, Abbott, Exactech and RTI.

Pam Cowart leads clinical affairs and compliance at MiRus. She combines cardiovascular nursing experience with medical-device clinical work, including heart-failure programs at CardioMEMS.

Jordan Bauman leads quality and regulatory affairs at MiRus. His experience spans medical-device development, regulatory submissions, reimbursement and commercialization for cardiovascular, orthopedic and spinal products.

Mahesh Krishnan is Chief Commercial Officer at MiRus. His health care experience includes orthopedic imaging at Carestream, spine products at DePuy Synthes, and marketing, sales and operating roles at Philips and Alliance Healthcare.

David Toney is MiRus’s Chief Financial Officer, joining in February 2022. His previous work included finance and operational leadership at Mohawk and finance, accounting and product-marketing roles at Seagate Technology and Chiaro Networks.

Interventional cardiologist and medical-device entrepreneur Jay Yadav founded MiRus and serves as CEO. Earlier ventures included CardioMEMS and Angioguard. His own biography describes work on stroke and heart-failure treatments, scientific publications and medical-device inventions. MiRus’s current focus combines novel implant alloys with orthopedic and cardiovascular technology.

Noah Roth is MiRus’s Chief Operating Officer. He has a background in engineering and law and led development of the MoRe alloy at Icon Interventional Systems. His earlier medical-device work included embolic and vascular technology.

MiRus LLC is a privately held medical-device and biomaterials company headquartered in Marietta, Georgia. Its own company profile reports founding in 2015 and launch in 2016. Led by interventional cardiologist Jay Yadav, it develops proprietary molybdenum-rhenium (MoRe) superalloys, implants and procedural systems for spinal, orthopedic and structural-heart disease. Its platform also includes surgical navigation and remote physiological monitoring. MiRus reports FDA 510(k) clearance of its first MoRe spine implant in 2019 and subsequent product-specific clearances, including the IO Expandable Wedge Osteotomy System announced in February 2026; this does not constitute approval of every product or disease indication. Its SIEGEL transcatheter aortic valve remains investigational and was not approved for commercial distribution in any country in the May 2026 announcement. The STAR randomized pivotal trial had begun enrolling patients in April 2026 under investigational authorization. In July 2021 the company completed a USD65 million growth financing led by Mammoth Scientific and unnamed multigenerational family offices. Boston Scientific announced a USD1.5 billion strategic payment in May 2026 for approximately 34% minority equity and an exclusive TAVR acquisition option; its SEC filing specifies 33.75% nonvoting equity and a prior USD100 million payment included in a total USD1.6 billion paid package, with equity versus option allocation undisclosed. The additional USD3 billion option-exercise payments are conditional future consideration, not funded capital. MiRus remains a distinct minority-held company; a full acquisition of its TAVR business has not been verified as completed.

Albert J. Kooistra is published by Kvantify as an external Scientific Advisory Board member. Copenhagen associate professor studying data science for drug design; earned a computational medicinal-chemistry doctorate at Vrije Universiteit Amsterdam.

Allan Grønlund is published by Kvantify as Co-founder and CTO. Computer scientist specialising in machine learning and applied algorithms; earned an Aarhus computer-science doctorate and worked across academic and industrial applications of mathematical models.

Casper Kirkegaard is published by Kvantify as EVP, Head of Engineering. Engineering leader and applied-science software specialist with a geophysics doctorate from Aarhus University.

Caterina Vigliar is published by Kvantify as an external Scientific Advisory Board member. DTU assistant professor studying integrated quantum photonics, high-dimensional encoding and measurement-based quantum computation; holds a Bristol doctorate.

Christina Krogsgård Nielsen is published by Kvantify as COO. Operations executive with an Aarhus nanoscience doctorate and seven years at McKinsey, where she served as an engagement manager.

David Gloriam is published by Kvantify as an external Scientific Advisory Board member. Copenhagen pharmacology researcher studying computational receptor biology and G protein-coupled receptors; holds an Uppsala pharmacology and bioinformatics doctorate.

David Siebert is published by Kvantify as SVP, Global Head of Business Development. Scientific business-development executive with previous roles at Schrödinger, Syngene and Avantor. Holds a TU Wien medicinal-chemistry doctorate and a Zürich International Business School MBA.

Frank Jensen is published by Kvantify as an external Scientific Advisory Board member. Aarhus chemistry associate professor researching quantum mechanics and computational molecular modelling; holds a UCLA chemistry doctorate.

Co-founder of Kvantify. The issuer announced in August 2025 that he stepped back from his operational role and remained a shareholder and supporter; no current CEO role is asserted. Kvantify’s filed2024 annualreport gives his full name as Hans Henrik Hernesniemi Knudsen and lists him as managing director and a board member when approved in June2025.

Jörg Weiser is published by Kvantify as Executive Chairperson. Computational molecular-research executive who built businesses in Europe and Asia. Holds a Göttingen organic-chemistry doctorate and previously led Schrödinger international operations. Delphinus Venture Capital’s current portfolio directory additionally publishes an interim CEO capacity at Kvantify; Kvantify’s own current directory publishes Executive Chairperson.

Kasper G. Larsen is published by Kvantify as an external Scientific Advisory Board member. Aarhus computer-science professor heading its Algorithms, Data and Artificial Intelligence section, researching algorithms and theoretical machine learning; earned his doctorate at Aarhus.

Martin Ulmschneider is published by Kvantify as an external Scientific Advisory Board member. King’s College London computational-chemistry professor researching peptides, proteins and membrane interactions; holds a DPhil focused on membrane-protein simulations.

Morten Kjærgaard is published by Kvantify as an external Scientific Advisory Board member. Niels Bohr Institute associate professor researching quantum information, devices and experimental computation; holds a Copenhagen quantum-device-physics doctorate.

Niels Pørksen is published by Kvantify as an external Scientific Advisory Board member. LeanBio founder and physician with an Aarhus medical doctorate and PhD. Previously held Sanofi and Eli Lilly leadership responsibilities in diabetes and obesity therapeutics.

Nikolaj Thomas Zinner is published by Kvantify as Co-founder and CSO. Aarhus physics professor and quantum-technology researcher with a physics doctorate, working on quantum information and physics-based modelling and leading research collaborations.

Ove Christiansen is published by Kvantify as an external Scientific Advisory Board member. Aarhus theoretical-chemistry professor researching quantum and computational molecular predictions, with an Aarhus theoretical-chemistry doctorate.

Søren Galatius is published by Kvantify as an external Scientific Advisory Board member. Columbia mathematics professor researching algebraic topology and geometry; holds an Aarhus mathematics doctorate.

Tobias Holm Jerichow is published by Kvantify as CFO. Finance executive responsible for financial planning, infrastructure and fundraising support, drawing on finance and consulting experience. The public biography does not specify educational qualifications.

Hesperia Capital is a growth-equity investment firm launched by Rhett Hunter and Michael Papile in 2023. It backs mission-oriented operating businesses, including behavioral health, technology-assisted elder care, maternal healthcare, connected water infrastructure and environmental technologies. Its published approach bridges venture and later-stage capital through minority convertible-preferred investments, generally targeting companies approaching or generating profits. Hesperia Capital, LLC is the legal adviser identified in its March 23, 2026 regulator filing, CRD330733; the filing names both founders as managers and identifies three Delaware private vehicles. Published investment criteria are not individual check allocations. Legal vehicle sizes, final closing dates and a broader private staff directory are undisclosed. The profile uses the official domain’s cached ship favicon; the firm explains its S.S. Hesperia namesake on its own website.

Co-founder and legal manager of Hesperia Capital. His published background spans lending, financial advice and investing across businesses. He has advised entrepreneurs, family companies and boards on strategic planning, acquisitions, divestitures, buyouts and recapitalizations, and combines transaction experience with capital and operating advice.

Co-founder and legal manager of Hesperia Capital. His own biography describes experience in growth investing, corporate development, startup finance and investment banking. He has worked across Internet of Things businesses and emphasizes operational systems, financial infrastructure and the integration of hardware, software and cloud services.

FGV Capital, formerly Fiat Ventures, is the venture investment arm of the FGV operating platform. It backs pre-seed through Series A founders at the intersection of financial technology, financial access and AI, including technology for healthcare, commerce and financial infrastructure. The investment team draws on a platform built around growth marketing, distribution partnerships, finance, recruiting and an advisor network to help founders turn products into scalable businesses. FGV Capital’s investment portfolio is separate from the broader FGV platform’s consulting clients; the manager identifies fund and SPV investments in its portfolio directory.

Aaron Libbey is Chief Growth Officer at Altana and previously worked at Palantir, according to the current fund announcement.

Jason Pritzker is affiliated with The Pritzker Organization and co-founded 53 Stations, according to the manager’s advisor page.

Jesse Horowitz is Chief Product Officer at Oscar Health, according to the manager’s team page and fund announcement.

Neha Kumar brings payer and product experience at Datavant, where the current fund announcement identifies her as SVP of Product.

Serkan Piantino co-founded Facebook AI and was VP of Product at Reddit.

Vinod Mitta, MD, brings medical and healthcare policy experience. The manager page identifies Medical Officer experience at the Center for Medicare and Medicaid Innovation; the current fund announcement identifies him as SVP of Policy and Strategy at Formation Bio.

The manager identifies prior experience as Chief Operating Officer at Maycomb Capital.